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Chronic heart failure (CHF) is the common end-stage entity of many cardiovascular diseases. 
It is defined as the inability of the heart to supply adequate blood in response to systemic 
demands. Clinical symptoms include decreased exercise capacity, shortness of breath, 
fatigue and edema. The incidence of CHF is 2-3% in developed countries, and rises sharply 
to 10% in those aged 75 years and older 1. Treatment of CHF has improved over the past 
decades, by treatment options including angiotensin converting enzyme inhibitors, beta-
blockers, aldosterone antagonists and angiotensin receptor blockers. Despite this success, 
CHF is still characterized by significant mortality with a 5-year mortality rate of approximately 




Ischemic heart disease, hypertension, valve disease, myocarditis and cardiomyopathy are 
the main causes of CHF development 1. All of these pathologic conditions lead to a series of 
molecular, cellular and interstitial changes in the heart termed as cardiac remodeling 4. 
Cardiomyocyte hypertrophy (growth) is one of the main remodeling processes triggered by 
biomechanical stress on the heart and/or neurohumoral changes (Figure 1) 5. This is 
accompanied with enhanced sarcomere organization and re-expression of fetal genes such 
as atrial natriuretic peptide (ANP) 6. This is considered to be an adaptive response to keep 
cardiac output within the normal range and to decrease ventricular wall stress. In the short 
term, this is believed to be a beneficial compensatory mechanism (compensated stage), but 
in the long run these processes can lead to CHF (decompensated stage) 7. In addition to 
growth of cardiomyocytes, rearrangement of cardiac muscle fibers, and accumulation of 
extracellular matrix components, fibrosis, occur during pathological hypertrophy 7. The latter 
processes are nearly absent in physiological hypertrophy, caused by exercise or pregnancy 
(Figure 1) 8. It has been suggested that it is the nature of the stimulus, not whether it is 
intermittent or sustained, that determines the kind of hypertrophy 9. So far, however, the 
molecular mechanisms are still poorly understood and a comprehensive view on the genes 
involved is still lacking. 
 
Altered expression pattern in CHF 
Alterations in gene expression have been described in cardiac remodeling and CHF. These 
changes in gene expression patterns often reflect the fetal gene expression patterns and it is  






generally believed that in CHF cardiac expression returns to the fetal gene program. Atrial 
natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are probably the best 
documented members of the fetal gene program. ANP is predominantly synthesized in the 
atria, while BNP is mainly expressed in the ventricles of the adult heart 10. These extracellular 
proteins are secreted by the heart with a strong elevation during HF 11. These peptide 
hormones can therefore be used as plasma markers for HF and because of its stability the 
NT- proBNP form is generally used as a clinical HF marker. Upon their release, ANP and 
BNP show diuretic, natriuretic and vasorelaxant effects. Besides this, ANP and BNP also act 
as paracrine factors,exerting antihypertrophic and antifibrotic effects in the heart 12. Not all 
gene expression changes during HF development appear, however, to be beneficial. The 
cardiac isoform of the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA2a) is a 
calcium ion (Ca2+) pump powered by ATP hydrolysis. SERCA2a has an important role in 
cardiomyocyte Ca2+ regulation 13 and in HF, SERCA2a expression is significantly decreased, 
which leads to poor Ca2+ handling and a deficient contractile function 14, 15. Although it is still 
debated whether return to the fetal gene program is in general beneficial or detrimental, the 
examples above show that per gene the effects on HF development and progression have to 
be determined. This will require specialized and genetically tractable HF models.   
 
 







In vivo and in vitro models to study heart failure 
 
During the past decades, several models have been developed to investigate molecular 
mechanisms, pathology, progression, complication and treatments of CHF. Among them, 
animal models, especially rodent models, remain the most popular tool for providing insights 
into CHF. Multiple intervention techniques have been developed to generate HF in rodents 16, 
as outlined in Table 1. Moreover, rodents offer many advantages such as small size, low cost, 
easy housing and care and most important genetic manipulation of mice and to a lesser 
extent also rats is relatively easy. As 99% of the human genes have orthologs in mice, gene 
targeting technology allows generation of transgenic mice to mimic patient situations 17 and 
to investigate cardiac specific functions of particular genes.  
 
Table 1. Rodent models of heart failure 
Aetiology Techniques Advantages Limitations 
Pressure overload Aortic banding Valuable to study 
hypertrophy and 
transition to heart 
failure. 




Volume overload Aortocaval shunt No thoractomy, simple 
and relatively easy 
technique. 
Rather a model of 
circulatory failure than 
heart failure. 
Myocardial ischemia Coronary artery 
ligation 
Difficult and rather high 
drop-out rates. 
Variation of infarct size, 





Insertion of osmotic 
minipumps with 
neurohormones  
Easy to perform and 
reproducible. 
Somewhat artificial infusion 
of high doses of 
neurohormones. 
Systemic hypertension Ren2; SHR; SHHF; 
Dahl salt sensitive 
rats 
Non-invasive, does not 
require intervention for 
disease induction.  
Heart failure develops 
already at a young age. 
Genetic modifications Transgenesis or 
knock out 
Allows to study the 
cardiac role of one 
particular gene.  
Often extreme conditions. 
E.g. no expression at all or 
very high overexpression. 
 
Besides in vivo animal models, cultured primary rat neonatal cardiomyocytes have 
been widely used to study cardiomyocyte hypertrophy in vitro. A number of extracellular 
stimuli, including endothelin-1 (ET-1), isoproterenol, transforming growth factor-β, tumor 
necrosis factor-α, insulin-like growth factor-I, and angiotensin II (Ang II) can individually 
induce hypertrophy in these in vitro cultured cardiomyocytes 18-22. However, since CHF is 
multifactorial syndrome and genetic, systemic and environmental factors play important roles, 






there are no perfect models that can reproduce completely the human situation. Therefore, 
depending on the research question multiple models might be required to answer specific 
problems. 
 
Scope of this thesis 
 
As outlined above, cardiac remodelling is accompanied by changes in gene expression and 
these changes could have beneficial or detrimental roles in CHF development. In this thesis 
we searched for novel genes with altered gene expression profiles in multiple HF and 
hypertrophy models. This resulted, amongst others, in the identification of a novel gene, 
termed Dhrs7c, which is downregulated during heart failure. An initial characterization of 
Dhrs7c was performed and a transgenic animal model was generated to explore its potential 
role in heart failure development.  
In Chapter 2, we review gene expression changes in heart failure and the process 
of cardiac remodeling. In Chapter 3, we describe the isolation and culturing of primary 
neonatal cardiomyocytes and tested whether an anti-mitotic drug that inhibits Plk1activity 
could improve purity of this culture by blocking fibroblast proliferation. Chapter 4 describes 
how we identified genes associated with HF/hypertrophy development by combining gene 
expression data obtained from in vitro and in vivo experiments. In Chapter 5, a basic 
characterization of one of the identified genes, termed Dhrs7c, is presented. In Chapter 6, 
the generation and characterization of a transgenic mouse with cardiac specific over-
expression of Dhrs7c is described. Finally, in Chapter 7 we will discuss the findings 
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Hypertrophy and fibrosis  










Heart failure (HF) is characterized by reduced cardiac output and an increased venous return. 
HF is often the common final entity of many cardiovascular diseases, such as pressure 
overload (hypertension), volume overload (mitral regurgitation), myocardial infarction, 
myocarditis and cardiomyopathy. Despite these diverse aetiologies, HF patients share many 
common features. Clinically, HF patients have often decreased exercise capacity, shortness 
of breath, fatigue and edema. Prognosis for HF is still poor with a mortality rate of 
approximately 50% within 5 years 1. HF is a chronic disease and with the ageing population 
the incidence of HF will increase and hence the burdens on our health care systems 2. 
 
2.1. Cardiac remodeling 
 
Cardiac remodeling mostly refers to ventricular remodeling and can be defined as any 
structural and functional change of the heart before and during HF, such as heart size, shape 
and mass 3. In the beginning, it is a compensatory reaction of the heart to reduce stress on 
the ventricular wall in response to changes in afterload (pressure load), preload (volume load) 
or myocardial injury 4. However, continued remodeling may not be necessary to maintain the 
integrity of the circulation 4. Progressive remodeling is considered as an adverse event that 
leads to development and progression of HF 3, 5. 
One of the major features of cardiac remodeling is cardiac hypertrophy, which refers 
to the increase of heart mass and/or size. Cardiac hypertrophy can be triggered by a 
combined action of mechanical stress and humoral trophic factors resulting in cardiomyocyte 
growth 6, 7. It is generally believed to be an adaptive and protective mechanism since it also 
occurs in athletes and pregnant women (physiological hypertrophy). This physiological 
hypertrophy is reversible and does not decompensate to heart failure, whereas, hypertrophy 
associated to cardiovascular diseases (pathological hypertrophy) may lead to heart 
decompensation, eventually resulting in ventricular dilation and HF 8. Another major feature 
of cardiac remodeling is the occurrence of cardiac fibrosis, which is the excess deposition of 
collagens and other extracellular matrix (ECM) proteins. Normal fibrillar collagens form a 
network between different cell types within the myocardium and are essential for maintaining 
cardiac geometry during systole and diastole of the heart 9, 10. Abnormal accumulation of 
collagen stiffens the heart and affects both systolic and diastolic function 11. Fibrosis also 
impairs mechano-electric coupling of cardiomyocytes resulting in increased risks of 
arrhythmias 12, 13. Furthermore, excessive accumulation of collagen results in reduced 





capillary density and increases oxygen diffusion distance, which in turn affects cardiomyocyte 
metabolism and performance and ultimately deteriorates heart function 4, 14. It is important to 
note that fibrosis happens predominantly in pathological hypertrophy and is nearly absent in 
physiological hypertrophy 15. 
Besides hypertrophy and fibrosis, apoptosis and necrosis of cardiomyocytes may 
also occur in the remodeled heart as well as infiltration of inflammatory cells, and changes in 
capillary densities 16. This review will, however, be focused on the cellular and molecular 
changes in hypertrophy and fibrosis. 
 
2.2 Cardiomyocyte hypertrophy 
 
2.2.1 Cardiomyocytes and hypertrophic stimuli  
The heart is predominantly composed of three cell types, cardiomyocytes (30-40% of all 
cells), fibroblasts (60-70% of all cells) and endothelial cells (1-2%) 17. In addition several 
other cell types are present in low numbers, including smooth muscle cells, macrophages, 
monocytes and others.  
Cardiomyocytes are the major functional cells in the heart and as a result of their 
large cell size build up 70-80% of the total heart mass 18. It is the contraction of 
cardiomyocytes that allows the heart to function as a pump. Therefore, changes in 
cardiomyocyte numbers or function can have major effects on the pump capacity of the heart. 
Cardiomyocytes are terminally differentiated cells and lose their ability to proliferate after birth. 
Therefore, although changes in heart rate can compensate for temporal changes in body 
demands, sustained changes rely on growth (hypertrophy) of cardiomyocytes, rather than on 
cell proliferation, or vice versa in a decrease in cell size (atrophy) 19.  
Cardiomyocyte hypertrophy induction is a complex process, but is basically driven 
by two different kinds of stimuli, namely biomechanical stress and neurohumoral factors 20. 
Biomechanical stress in the heart refers to any stress leading to hemodynamic changes. In 
vitro, cardiomyocyte stretch can trigger cell hypertrophy directly, without obvious contribution 
of neurohormones, but in vivo most of the hemodynamic overload is accompanied by 
changes in neurohumoral factors 21. These factors include angiotensin II (AngII), endothelin-1 
(ET-1), catecholamines, and growth factors, like IGF-1. These factors can also directly 
induce hypertrophy in cultured cardiomyocytes in vitro 22-26.  
 
2.2.2 Hypertrophic signaling 







specific 7-transmembrane G-protein-coupled receptors (GPCRs) that are present on the cell 
membrane of cardiomyocytes 27. GPCRs are intracellular coupled to trimeric G-protein 
complexes consisting of an α, β and γ subunit. Upon activation of the receptors the α subunit 
is liberated from the stable βγ complex and both the α and the βγ complex can subsequently 
activate downstream effectors (Figure 1) 28. The ET-1, AngII and α-adrenergic GPCRs are 
intracellular coupled to the α subunits Gq or G11 (Figure 1). Stimulation of the GPCRs 
liberates Gq/11 which activates phospholipase C (PLC) resulting in the generation of 
diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3) from phosphatidylinositol-4,5-
bisphosphate (PIP2) (Figure 1). DAG subsequently stimulates protein kinase C (PKC), which 
on its turn activates downstream signaling pathways, like the Mitogen Activated Protein 




Figure 1. Simplified depiction of signal transduction pathways controlling gene expression and 
cardiomyocyte hypertrophy. JNK, c-Jun N-terminal kinases; ERK, extracellular signal-regulated kinases; 
TRK, tyrosine receptor kinase; NE, norepinephrine; LTCC, L-type calcium channel. Other abbreviations 
are mentioned in the text. 





IP3 on the other hand enhances liberation of Ca2+ from intracellular stores and 
hence increases Ca2+ / Calmodulin (CaM) levels resulting in the activation of amongst others 
the Calcineurin / Nuclear Factor of Activated T-cells (NFAT) pathway 30. In parallel the Gβγ 
dimer complex can activate PI-3-Kinase (PI3K) resulting in the activation of the Akt (also 
termed PKB) kinase pathway 31. The activation of these pathways will increase protein 
synthesis and activate transcription factors finally resulting in hypertrophy development.  
Also β-adrenergic signaling is mediated via GPCRs and the β1-receptor is the most 
prominent β-adrenergic receptor in the adult heart. In contrast to the afore mentioned GPCRs 
this receptor is coupled to GS and activates adenylate cyclase resulting in elevated cyclic-
AMP (cAMP) levels and activation of protein kinase A (Figure 1) 32. PKA can phosphorylate a 
number of proteins, including the ryanodine receptor (RyR), phospholamban (PLB) and 
troponin I, resulting in increased contraction and relaxation rates of the heart. However, it 
also activates directly or indirectly pathways that induce cardiomyocyte hypertrophy (Figure 
1). In addition to the β1-receptor the heart also contains a β2-receptor and this receptor is 
coupled to both Gs and to Gi. The latter can inhibit adenylate cyclase and hence could 
counteract the effect of the β1-receptor 33. In this respect it is also important to note that in HF 
the ratio of β1 to β2-receptors is shifting in the favor of the latter 34.  
Whereas the neurohormonal factors act via GPCRs, most growth factors, like IGF-1 
or PDGF, act via tyrosine protein kinase receptors 35. Binding of the particular growth 
hormone to its receptor result in the activation of these tyrosine kinase receptors and binding 
of numerous scaffolds to these receptors. This finally leads to the activation of number of 
downstream signaling pathways, including the MAPK and PI-3-K/Akt pathways and hence in 
hypertrophy development (Figure 1). Although neurohormonal and growth factor signal 
transduction pathways have been explored in great detail, biomechanical sensing pathways 
are still less understood. Biomechanical stretch sensing includes stretch-activated ion 
channels, cell surface receptors such as integrins, cadherin complexes involved in cell-cell 
adhesions and signaling from the sarcomere 36, 37. Again, this result in the activation of a wide 
range of signaling pathways, including the above mentioned hypertrophy inducing pathways 
(Figure 1).  
Although all signaling pathways are often depicted as linear pathways there is a vast 
amount of cross-talk between these pathways. Moreover, there is a precise temporal and 
spatial control of these pathways and the presence of numerous subtypes of the different 
signaling proteins (e.g. PLCβ, γ, δ, ε, ζ, η) generates and much more complex and dynamic 
situation as depicted in Figure 1. It is the intricate balance between these different pathways 








2.2.3 Modulating major hypertrophic signalling pathways in animal models 
Despite the detailed investigations of the molecular pathways in cardiomyocyte hypertrophy, 
so far no treatments options have been generated focused on these pathways. One reason 
for this is the fact that these pathways do not appear to be simple on/off switches, but instead 
a delicate balance in activities appears to determine the downstream effects. For example, 
Shiojima et al.38 reported that transgenic mice overexpressing Akt-1 showed modest growth 
of the heart in the short term similar to physiological hypertrophy. However, sustained long 
term overexpression generated excessive cardiac hypertrophy contributing to heart failure in 
these mice due to inhibition of coronary angiogenesis 38. Akt1-deficient mice on the other 
hand did not show any specific cardiac phenotype under normal conditions 39. Surprisingly, 
however, DeBosch et al found that in response to a TAC-operation Akt1-deficient mice had 
higher ANP and β-MHC expression and a higher heart weight due to cardiomyocyte 
hypertrophy, as compared to wild type mice 39. Thus depending on the condition, both low 
and high Akt1 activity could induce cardiac hypertrophy. Interestingly, exercise mediated 
hypertrophy was absent in Akt1 deficient mice indicating that Akt1 is essential for 
physiological, but not pathological hypertrophy. Together, these results show that the 
strength and duration of Akt1 signaling appears to determine whether this results in 
physiological or pathological hypertrophy, or can even suppress growth in certain conditions. 
This exemplifies the complexity and sensitivity of the system and shows that one should be 
careful with the interpretation of deletion and overexpression studies.   
Compared to PI3K/Akt signaling, the calcineurin/NFAT signaling pathway seems to 
be specifically linked to pathological cardiac hypertrophy. Calcineurin activity and protein 
levels are upregulated in heart tissue from both exercise- and TAC-induced cardiac 
hypertrophy models, as well as in dilated heart failure 40, 41. Transgenic mice expressing a 
truncated constitutively active form of calcineurin demonstrated a 2-3 fold increase in heart 
size that rapidly progressed to dilated heart failure within 3 months 42. Mice with deficient 
calcineurin-β showed resistance to diverse hypertrophic stimuli, suggesting that calcineurin 
functions as a central regulator of cardiac hypertrophy resulting from these stressors 43. 
However, recent results show that overexpression of a calcineurin splice variant (β1) 
improves cardiac function and attenuates hypertrophy post-MI 44. This again exemplifies the 
complexity of these pathways. Using the calcineurin inhibitor cyclosporine pressure-induced 
cardiac hypertrophy could be suppressed in mice 45, 46. However, despite attenuation of 
pressure overload induced hypertrophy, it has also been shown to enhance susceptibility to 
decompensation and HF 47. Moreover, since cyclopsporine is a strong immunosuppressant, 
by targeting NFAT in T cells its use in a clinical setting for treating HF will not to be feasible. 





Thus, although this pathway could be a potential target, its prominent role in many other cell 
types will make it difficult to be used as a HF therapy.  
Also the mitogen-activated protein kinases (MAPK) signaling pathways, in particular 
the ERK pathway has been linked to cardiac hypertrophy and ERK activity is induced during 
HF. Transgenic mice with increased activity of ERK 1/2 showed significant cardiac 
hypertrophy 48 and activation of ERK1/2 induced more cardiac hypertrophy following TAC 49. 
However, because of its importance in many different cellular processes and its intertwining 
with many other pathways it will be difficult to generate specific HF therapeutic approaches 
around this pathway. Therefore, pharmaceutical targeting of these signaling pathways to 
treat HF might be more difficult than originally anticipated. Downstream targets of these main 
pathways, which could potentially allow more specific and more subtle targeting, may 
therefore comprise altenative targets.  
 
2.2.4 Gene expression changes in cardiac hypertrophy and the fetal gene 
program 
The intracellular signaling pathways that are triggered by hypertrophic stimuli transduce 
these signals to the nucleus resulting in altered gene expression patterns (Figure 1). The 
downstream transcription factors of these pathways are critical to regulate hypertrophy 
specific gene expression. These transcription factors include GATA4 50, GATA6 51, NFAT 52, 
Nkx2.5 53, nuclear factor κB (NFκB) 54, myocyte enhancer factor 2 (MEF2) 55, serum response 
factor (SRF) 56, Brg1 57, Hand 1/2 58 and Smad transcription factors 59. Many of these 
transcription factors are thought to mediate the reactivation of the “fetal gene program” 60, 61. 
The fetal gene program refers to the fetal gene profile that returns in the adult cardiomyocyte 
in response to stress triggers like pressure overload, myocardial infarction, cardiac 
arrhythmias, valvular disease, and genetic mutations in contractile proteins 62. One 
characteristic of the fetal gene program is the re-expression of atrial natriuretic peptide (ANP 
(NPPA)) amongst others (see Table 1). During development the expression of ANP is an 
early hallmark for the differentiating working myocardium of the atria and ventricles of the 
heart. ANP expression is down-regulated in ventricles at the end of fetal development and 
around the time of birth ventricular ANP expression is further downregulated to very low 
levels, while atrial expression remains high 63, 64. During HF ANP expression is reinduced in 
the adult ventricle. A large number of regulatory elements were found in the 700 bp proximal 
promoter fragment, including binding sites for GATA4-6, Mef2c, SRF, Nkx2.5 and others 65. 
In vivo analysis revealed, however, that fetal ventricular activity is provided by region 
between -127 to -27 kb, whereas adult re-expression in the ventricle requires regulatory 







adult re-expression of ANP during HF are mediated by different promoter elements. This 
results show that divergent regulatory pathways may activate fetal gene expression in the 
fetal heart versus the failing adult heart. The term “fetal gene program” might therefore be 
somewhat misleading. These results also show that proximal promoter binding studies 
should be taken with caution and that the in vivo situation might be much more complex. 
 
Table 1. A selection of genes belonging to the fetal gene program  
Genes Adult Fetal Hypertrophy 
α-MHC ↑ ↓ ↓ 
β-MHC ↓ ↑ ↑ 
SERCA2 ↑ ↓ ↓ 
ANP ↓ ↑ ↑ 
BNP ↓ ↑ ↑ 
α-SKA ↓ ↑ ↑ 
GLUT4 ↑ ↓ ↓ 
Arrows indicate increased or decreased expression. 
 
2.2.5 Beneficial and detrimental gene expression changes 
As mentioned above ANP expression is reactivated in the failing myocardium. ANP is a 
circulating hormone excreted by the heart and plays an important role in the regulation of 
fluid volume and blood pressure 67, 68. ANP, as well as BNP, functions to reduce the extra 
fluid from the circulatory system by inhibition of renal tubular NaCl reabsorbtion 69. The 
absence of ANP results in salt-sensitive hypertension and cardiac hypertrophy in ANP knock-
out mice 70. Whereas ANP transgenic mice exihibit lower arterial blood pressure; in acute 
blood volume expansion generated by intravenous infusion, the mice show enhanced diuretic 
and natriuretic responses 71,72. ANP has therefore a positive effect since it reduces blood 
pressure and unloads the failing heart.  
During cardiac hypertrophy and HF the main myocardial energy substrate switches 
from fatty acids to carbohydrates. This switch reflects the fetal situation in which glucose is 
the main metabolic substrate of the heart. Also at the gene expression level changes in 
numerous metabolic enzymes has been observed, although it appears that both glucose and 
fatty acid metabolism encoding genes are downregulated 73. Since the changes in gene 
expression of some metabolic enzymes do not directly correlate with changes in enzyme 
levels and activities it is still under debate whether these changes directly contribute to this 
switch 74. Since carbohydrate metabolism requires less oxygen as compared to fatty acid 
metabolism, this switch is often considered to be beneficial, at least for the ischemic heart. 
Emerging evidence shows that this fetal pattern metabolic shift can improve the contractile 





function of the failing heart 75. Inhibition of fatty acid β-oxidation by Trimetazidine (1-(2,3,4-
trimethoxybenzyl) piperazine dihydrochloride) has been reported to improve left ventricular 
function in patients with chronic HF 76, 77. The beneficial impact shown by these small clinical 
trials suggests that targeting metabolism could be a promising strategy for HF and hence 
deserves further investigations. 
Cardiac remodeling is also accompanied by changes in gene expression of 
contractile sarcomere proteins, in particular the myosin heavy chains (MHC). Two types of 
MHC, α- and β, are specifically expressed in the heart 78, 79. α-MHC has a higher adenosine 
triphosphatase activity and higher filament sliding velocity than β-MHC, but the latter can 
generate cross-bridge force with a higher economy of energy 80, 81. The heart contractile 
performance is correlated with the relative amount of each MHC. More α-MHC expression 
results in a increased contractile velocity, whereas hearts with a higher β-MHC content 
generate force in a more economic way 82.  In rodent ventricles more than 90% of MHC is α-
MHC 83-85. Several investigators have reported an increase in β-MHC and decrease in the α-
MHC isoform in hypertrophied ventricles 86, 87 and in heart failure. The level of β-MHC closely 
correlates with the degree of cardiac hypertrophy 85. Although the shift from α- to β-MHC can 
preserve energy, increased β-MHC also reduces the velocity of shortening, which may have 
a detrimental effect on failing hearts and promote disease progression 88, 89. Although in 
human β-MHC is the predominant form in the heart, as opposed to rodents, also in humans 
β-MHC expression increases during HF, although these effects are less pronounced as in 
rodents 90, 91.  
   Although the examples above indicate predominantly beneficial effects for the fetal 
gene program, other changes appear to be detrimental. One example is the downregulation 
of the Ca2+ activated sarcoplasmic/endo-plasmic reticulum ATPase (SERCA). SERCA is the 
main transporter for Ca2+ from the cytoplasm to the sarcoplasmic/endoplasmic reticulum 92. 
Using ATP as an energy source, SERCA transports Ca2+ form the plasma to the 
sarcoplasmic reticulum in order to maintain calcium homeostasis within cells. This process is 
essential for calcium handling and excitation-contraction coupling in cardiac and skeletal 
muscles. In mammals, three isoforms of SERCA have been identified, among them SERCA2 
is most prominently expressed in the heart. SERCA2 mRNA increases markedly after birth, 
sustains at high levels for a long period in young rodents and decreases in ageing animals 
thereafter 93. Whereas during initial stages of hypertrophy development SERCA2 expression 
(and activity) increases and  may improve the function of the hypertrophied rat hearts 94, in 
heart failure, SERCA2 decreases at mRNA and protein level 95-99. It has been reported that 
the decrease of SERCA2 (activity) contributes to the functional abnormalities in the ageing 







adenovirus-mediated gene transfer and observed that increased levels of SERCA2a can 
improve heart function in ageing rat 100. Moreover, the calcium upregulation by percutaneous 
administration of gene therapy in cardiac disease (CUPID) phase 1/2 study that enrolled a 
total of 39 patients with severe heart failure randomized to adeno-associated virus-mediated 
transfer of SERCA2a or placebo has recently been presented 101.The CUPID trial suggests 
adequate safety and potential efficacy warranting further studies to evaluate this new 
treatment option in heart failure 102. This also indicates that gene or pharmaceutical targeting 
of fetal gene program components could potentially attenuate hypertrophy and hence might 




2.3.1 The extracellular matrix and fibrosis 
Cardiac fibrosis is a hallmark of pathological hypertrophy and contributes to heart failure 
progression. Fibrosis is characterized by disproportional accumulation of extracellular matrix 
(ECM) componts The ECM is composed of elastin, fibrillin, fibronectin, proteoglycans, 
basement membranes and fibrillar collagen 103. The synthesis and degradation of ECM in the 
heart is a dynamic process. It is estimated that collagens in the heart are renewed at a rate of 
0.6% per day with an average half-life of 80-120 days 104. The major function of the ECM is to 
provide a structural backbone to preserve tissue architecture in both systolic and diastolic 
phase. During systole, the ECM transmits force generated by single cardiomyocytes into 
organized cardiac contraction. Whereas during diastole, the ECM network prevents 
cardiomyocyte overstretch and slippage, and hence protects the heart against deformation 
105
. Due to its structural functions, ECM was initially considered less important except for 
reparative (replacement) fibrosis in which matrix components appear at sites of cell loss. 
However, besides the structural functions, the ECM also serves as modulator of growth, 
tissue differentiation, and angiogenesis 106, 107. Studies from animals and patients indicate 
there is another type of fibrosis, reactive fibrosis, which occurs in the cardiac interstitium and 
peri-vascular area in the absence of myocyte loss 104. This reactive fibrosis is an adaptive 
response to preserve the force generating capacity of the hypertrophied heart, especially in 
the beginning of disease development. However, excessive fibrosis can disturb normal 
contractility and cardiomyocyte function. The amount of fibrosis is dependent on changes in 
the balance of matrix formation and degradation. In addition, the ratio between the different 
matrix components and the degree of collagen crosslinking are associated with cardiac 
function. This is not only because of changes in stiffness of the matrix, but rearrangements of 
the collagen network also affect the conductance of electrical signals 108, 109. 





2.3.2 Fibroblasts and myofibroblasts in fibrosis  
Fibroblasts play an essential role in generating the extracellular matrix and constitute about 
60-70% of all cells in the heart, but due to their relative small size these cells only make up 
20-30% of the heart mass. Fibroblasts are poorly defined cells (no specific markers) and are 
present in all tissues in the body. These cells do, however, contain certain proteins absent in 
cardiomyocytes, including vimentin and the collagen receptor Discoid domain receptor 2 108. 
Fibroblasts, in particular myofibroblasts, secrete large amounts of extracellular matrix 
components, like collagens, fibronectin, eleastins, as well as enzymes modulating the ECM, 





Under pathological conditions fibroblasts tansform into an active phenotype called 
myofibroblasts, which is essential for the development of cardiac fibrosis (Figure 2) 111. This 
myofibroblasts presents characteristics in between those of fibroblasts and smooth muscle 
cells 112. In culture this differentiation can be induced by stretch and inflammatory mediators 
present in the diseased heart, like TGF-β and IL-1 and IL-6 and differentiation requires 
adhesion and integrin signaling 113.The steps in this process are not well understood and, in 
particular, the molecular mechanisms by which this differentiation occurs in vivo are unknown. 
Figure 2 Fibroblast to myofibroblast 
transition and ECM modulation. Fibro-
blasts transform to myofibroblasts in 
response to cardiac stress signals, 
including mechanical stretch, hormones 
and cytokines. The myofibroblasts have 
increased capacity of ECM synthesis 
and can also alter the balance of MMPs 
and TIMPs to promote fibrosis. These 
alterations contribute to cardiac dys-
function. Figure adapted from Berk BC, 








As compared to fibroblasts, myofibroblasts show increased migration activity and increased 
collagen synthesis and proinflammatory cytokine secretion as compared to fibroblasts. These 
cells express several smooth muscle markers (early differentiation markers), such as smooth 
muscle α-actin, tropomyosin, nonmuscle myosin heavy chain-B (SMemb), and smooth 
muscle 22α 114-116. Besides being a marker for the fibroblast to myofibroblast switch, α-SMA 
has been indicated to have contractile properties and play an important role in the generation 
of myofibroblast contractile force 117. More stringent smooth muscle markers (late 
differentiation markers) like smooth muscle myosin heavy chains are not expressed in 
myofibroblasts 118.  
 
2.3.3 Changes in (myo)fibroblast gene expression during HF 
In the healthy heart expression and secretion of matrix components is mainly dependent on 
fibroblasts in the heart, whereas in the stressed heart the myofibroblast becomes the major 
source for the production of matrix components. The hypersecretory ability of this cell type 
requires altered expression of a number of matrix genes including collagen type I and III (Col 
I and III). Col I and Col III represent about 80% and 10% of the total ECM in the heart, 
respectively 104. Col I gives the heart its tensile strength and makes the myocardium stiff 
when the level is increased. Col III has a resilience ability that keeps the structural integrity 
and distensibility of the heart 104. Changes in collagen expression occur during HF 
development and the ratio of these differences might provide information about the type of 
dysfunction 119. Kasner et al. for example observed that both mRNA and protein expression 
of Col I, but not Col III, were increased  in diastolic HF patients with normal systolic function 
and  the Col I level correlated with the diastolic dysfunction 120.  
Similar to the different collagen isoforms, also a delicate balance exists between 
multiple metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). 
Since the turnover of ECM in heart tissue depends principally on these proteins, changes in 
relative expressions and activities will affect matrix formation. MMPs are secreted as inactive 
precursors (Pro-MMP) which must be activated by proteolytic cleavage of the amino terminal 
propeptide domain. In vitro, inflammatory hormones, like IL-1 appear to downregulate 
expression of MMPs, whereas profibrotic hormones like angiotensin II decrease expression 
of several MMPs. In vivo, after MI, MMP1 expression is initially increased and collagen 
degradation exceeds synthesis 121. At later stages, however, ECM synthesis exceeds 
degradation and MMP expression is decreased, whereas TIMP expression is increased, 
resulting in a decreased MMP/TIMP ratio 121. Interestingly, TIMP-1 knockout mice 
demonstrated less myocardial fibrillar collagen content in association with increased left 
ventricle end-diastolic volume and heart mass 122. Similar effects were indicated in TIMP-3 





deficient mice 123. In addition to the direct inhibition of MMPs, the TIMPs also have influence 
on fibroblast that lead to collagen accumulation. Adenoviral mediated TIMPs overexpression 
in fibroblast indicated that all TIMPs can promote fibroblast proliferation and induce the 
fibroblast to myofibroblast switch 124.  
In summary, pathological stress on the heart results in a switch from fibroblasts to 
myofibroblasts, which have a phenotype in between fibroblasts and smooth muscle cells and 
express α-SMA. These cells express and hyper secrete a large variety of matrix components 
that contribute to matrix remodeling and contribute to HF development. Matrix proteins, like 
MMPs, TIMPs and collagen breakdown products, could be interesting biomarkers 125 and 




Cardiac stress induces major changes in gene programs, generating cardiomyocyte 
hypertrophy and fibrosis, which drive cardiac remodeling. Although major signaling pathways 
have been identified in these processes, targeting these pathways has, so far been 
unsuccessful in HF treatment. Targeting so called fetal gene program targets might be more 
rewarding, as exemplified by SERCA2a. Restoring the expression of SERCA2a during HF 
improves cardiac function and although this requires gene therapy this might be a rewarding 
approach. Identification and exploration of other fetal gene program genes could therefore be 
a fruitful enterprise. In addition, controlling fibrotic processes by influencing matrix remodeling 
genes and enzymes could provide an additional treatment strategy that requires further 
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BI 2536 is a new anti-mitotic drug that targets polo-like kinase 1 (Plk1) and is currently under 
clinical development for cancer therapy. The effect of this drug on cancer cells has been 
extensively investigated, but effects on primary dividing cells and differentiated non-dividing 
cells are scarce. We have investigated the effects of this drug on primary neonatal rat cardiac 
fibroblasts and on differentiated cardiomyocytes and explored the possibility to use this drug 
to enrich differentiated cell populations in vitro. BI 2536 had a profound effect on cardiac 
fibroblast proliferation in vitro and arrested these cells in mitosis with an IC50 of about 43 nM. 
Similar results were observed with primary human cells (HUVEC, IC50=30 nM), whereas the 
cancer cell line HeLa was more sensitive (IC50 of 9 nM). Further analysis revealed that 
prolonged mitotic arrest resulted in cell death for about 40% of cardiac fibroblasts. The 
remaining cells showed an interphase morphology with mostly multi- and micro-nucleated 
nuclei. This indicates that a significant number of primary fibroblasts are able to escape BI 
2536 induced mitotic arrest and apparently become aneuploid. No effects were observed on 
cardiomyocytes and hypertrophic response (growth) upon endothelin-1 and phenylephrine 
stimulation was normal in the presence of BI 2536. This indicates that BI 2536 has no 
adverse effects on terminally differentiated cells and still allows proliferation independent 
growth induction in these cells. In conclusion, cardiomyocytes could be enriched using BI 
2536, but the formation of aneuploidy in proliferating cells, most likely limits this in vitro 
application and does not allow its use in putative cell based therapies.  







Contamination with proliferating cells is often a serious problem in cell culture studies 
investigating differentiated or quiescent cell populations, since the former can easily 
overgrow the cell type of interest. Examples include cardiomyocyte and neurological cell 
research, while also in the field of stem cell differentiation for cell therapies this represents a 
common problem. To remove proliferating cells from differentiated cell populations, 
nucleotide analogues are often used like bromodeoxyuridine (BrdU) and arabinoside 1, 2, 
which are incorporated in the DNA of proliferating cells resulting in DNA damage check-point 
activation and cell cycle arrest. Since these drugs affect the genetic code they cannot be 
used in any subsequent therapy. Moreover, these analogues are also incorporated in 
mitochondrial DNA and can interfere with mitochondrial biogenesis of the differentiated cell 
population. Other methods, like FACS analysis often require specific antibodies and the 
throughput is often limited. With the development of more specific anti-cancer drugs, we 
decided to investigate the potential of the polo-like kinase 1 (Plk1) inhibitor BI 2536 3, 4 as a 
potential drug to eliminate proliferating cells from in vitro cultures containing terminally 
differentiated cardiomyocytes.  
Plk1 is a mitotic kinase, which is highly expressed in proliferating cells only during 
the G2 and M phase of the cell cycle. It has specific roles during mitotic progression, 
including centrosome maturation, spindle assembly, chromosome segregation and 
cytokinesis 5, 6. Plk1 consist of two domains, a C-terminal catalytic kinase domain and a N-
terminal polo-box-domain (PBD), which recognizes specific phosphorylated targeting 
sequences 7, 8 and is essential for its specific localisation and interaction with some of its 
substrates 7, 9, 10. Micro-injection of Plk1 antibodies  and siRNA based studies targeting Plk1 
have shown the essential role of Plk1 in mitotic progression in cancer cells 11-15. These 
studies revealed that functional interference with Plk1 resulted in a mitotic arrest with 
condensed chromosomes, monopolar spindles and non-matured centrosomes. Recent 
studies with small molecules targeting Plk1, have confirmed these effects, and moreover 
revealed late stage mitotic functions for  Plk1 3, 16. Following prolonged mitotic arrest, cell 
death (apoptosis) is induced in Plk1-inhibited cancer cells and hence Plk1 has been 
proposed to be a promising anti-cancer target 4, 17. 
Despite the large body of evidence in cancer cells, the role of Plk1 in primary cells 
has only been poorly investigated and conflicting results have been published. In primary 
fibroblasts, Plk1 antibody microinjection was shown to arrest these cells with a G2-like 
phenotype, in contrast to the mitotic arrest in cancer cells 11. G2-phase functions for Plk1, 







Nevertheless, the role of Plk1 in G2-M phase transition in mammalian cells under normal 
conditions is still under debate 5. Also siRNA studies showed different results in normal cells, 
as compared to cancer cells. In direct comparisons normal cells did not appear to be affected 
by Plk1 depletion, whereas cancer cells arrested in mitosis followed by cell death 12,13. 
Together with the facts that numerous cancer cells show increased Plk1 expression, these 
results further supported  that Plk1 could be a specific anti-cancer target 17.  
BI 2536 is currently the most intensively investigated Plk1 inhibitor 22. BI 2536 is a 
small molecule inhibiting Plk1 at subnanomolar concentrations in vitro (0.83 nM) and is 
equipotently active against human, mouse and rat Plk1 4. It was shown over 1000 fold more 
selective towards Plk1 as compared to 63 other kinases and only some activity against  the 
closely related kinases Plk2 and Plk3 were reported 3. BI 2536 has been tested on numerous 
human cancer cell lines in vitro, and tumor Xenograft models suggested prominent anti-
cancer activity 3. Several phase I and phase II trials have been performed 22-24, but its 
potential as an anti-cancer target still has to be established. The latest phase II trial study on 
five different cancer types was rather disappointing, showing only limited anti-tumor activity 24.  
Here we tested the potential in vitro application of this drug by studying the 
elimination of proliferating cells from cultures containing primary differentiated cells. We used 
a commonly used system in cardiac research consisting of partially purified primary 
differentiated neonatal cardiomyocytes. We describe the effects of BI 2536 on these 
differentiated cells as well as on primary cardiac fibroblasts and show detrimental effects on 




Reagents and chemicals 
Cell culture medium and serum were obtained from Lonza Benelux B.V. (Breda, The 
Netherlands) and penicillin-streptomycin and trypsin were from Invitrogen (The Netherlands). 
Mouse monoclonal anti-α-actinin antibody EA53 and mouse monoclonal anti-α-tubulin (B-5-
1-2) antibody were from Sigma-Aldrich Chemie B.V., rabbit polyclonal anti-troponin (ab9332) 
was from Abcam (Cambridge, MA, USA), FITC labelled anti-phospho-Histone H3 (Ser10) 
antibody was from Cell Signaling. Antibody Dylight 649 labelling kit was from Pierce 
Biotechnology (Rockford, IL, USA) BI 2536 was purchased from Axon Medchem (Groningen, 
The Netherlands) and dissolved in DMSO at a concentration of 100 µM. L-[4,5-3H]Leucine 
(37 MBq/ml; 5.85 TBq/mmol) was from GE Healthcare Europe (Diemen, Belgium) and Ultima 
Gold XR scintillation liquid was from Perkin Elmer (Groningen, The Netherlands). Unless 





otherwise stated all chemicals were purchased at the highest possible grade from Sigma-
Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). 
 
Neonatal rat cardiac myocyte and fibroblast isolation 
Neonatal rat ventricle myocytes were isolated from the cardiac ventricles of 1-3 days old 
Sprague-Dawley pups. For isolation we followed a previously described protocol 1,25. In short, 
hearts were removed from the thoracic cavity  and placed in a tube containing cold CBFHH 
solution (137 mM NaCl, 5.36 mM KCl, 0.81 mM MgSO4, 5.55 mM dextrose, 0.44 mM 
KH2PO4, 0.34 mM Na2HPO4, 20 mM HEPES, pH 7.4). Ventricles were separated from other 
tissue using scissors and cut into several pieces. Subsequently cardiomyocytes and 
fibroblasts were detached from the extracellular matrix by repeated incubation in CBFHH, 
supplemented with 2 mg/ml trypsin and 20 µg/ml DNase. Cells were collected by 
centrifugation and tissue clumps were removed by filtration. Subsequently, cells were 
preplated in cell culture dishes in 50 ml MEM medium with 5% FCS for 45 min. During this 
period most non-cardiomyocyte cells (mainly fibroblasts) attached to the dish, whereas 
cardiomyocytes remained in solution. The cardiomyocytes were subsequently transferred to 
separate tissue culture dishes and allowed to attach. Both fibroblasts and cardiomyocytes 
were subsequently cultured in DMEM medium containing 10% FCS.  
All animal studies were conducted in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals and approved by the Committee for Animal Experiments of 
the University of Groningen (Approval ID: DEC 5495). 
 
Cell culture 
Neonatal rat primary cardiac fibroblasts and cardiomyocytes and HeLa (S3) were cultured at 
37° C under 5% CO 2 in DMEM medium, supplemented with 10% FCS and penicillin-
streptomycin (100 IU/ml and 100 µg/ml, respectively). BI 2536 was added to a final 
concentration of 100 nM, unless otherwise stated. Corresponding control cultures received 
an equal volume of solvent (DMSO). Primary human umbilical vein endothelial cells (HUVEC) 
were obtained from the Endothelial Cell Facility (University Medical Center Groningen, The 
Netherlands). HUVEC were isolated from two umbilical cords and prepared as previously  
described 26, 27. Cells were cultured on 1% pre-coated gelatin plates (Greiner Bio-One) at 37° C  
under 5% CO2 in RPMI 1640 medium was supplemented with 20% FCS, 2 mmol/L L-
Glutamine, 5 U/ml heparin, 100 IU/ml penicillin, 100 µg/ml streptomycin and 50 µg/ml 
endothelial cell growth factor extracted from bovine brain.  HUVEC experiments were 








For FACS analysis attached cells were detached by trypsin treatment and collected by 
centrifugation together with free floating cells in the medium. After a PBS wash cells were 
fixed in 4% paraformaldehyde for 10 min at 4° C. Ce lls were subsequently washed with PBS 
and stored at 4° C in PBS until all samples from on e experiment were collected. 
Subsequently cells were treated with ice cold PBS+0.1% tritonX100 for 5 min and washed 
again with PBS. Cells were subsequently incubated in 100 µl PBS+1% BSA containing the 
indicated antibodies and propridium iodide (1 µg/ml) for 30 min at room temperature (RT). 
FITC labeled anti-phospho-Histone H3 (Ser10) antibody was used at a 1:200 dilution. Anti α-
actinin antibody was first labelled with DyLight 649, according to the manufacturer 
instructions (Pierce Biotechnology, Rockford, IL, USA). This labelled antibody was then used 
at a 1:100 dilution. FACS analysis was performed on a FACS calibur (Becton Dickinson) and 
data were analysed with WinMDI2.9. 
 
Quantitative Real-Time PCR 
Relative expression of ANP, Troponin and Periostin genes was determined by quantitative 
PCR (qPCR). Gene expression was determined by correcting samples for reference gene 
values (cyclophilin A), and values were expressed relative to the control group per 
experiment. Primer sequences were: Troponin T-1, cagaagaggttggtcctgatgaa; Troponin T-2, 
gcaccaagttgggcatgaa; Periostin-1, gatccacggagaaccagtc; Periostin-2, cccacctcctgtggaaatc; 
Cyclophilin-1, cctcataccagcgacgattc; Cyclophilin-2, atgtggaggagtctcacttc. 
 
Microscopy 
For cardiomyocytes, coverslips were coated with 1 µg/cm2 laminin (Millipore) for at least 
three hours. For fibroblasts non-coated coverslips were used and HUVEC cells were grown 
on coverslips coated with poly-lysine and 1% gelatin. Cells were grown on coverslips for the 
indicated time period and subsequently washed with PBS and fixed in paraformaldehyde 
solution for 10 min at RT. Cells were then permeabilised with ice cold PBS+0.5% Triton X100 
for 5 min and then washed with PBS. Antibody incubations were performed in PBS+1%BSA 
for 1 hour at RT. Primary antibodies used were mouse monoclonal anti-α-tubulin and rabbit 
anti-troponin. Secondary antibodies were: goat anti-mouse Alexa555 (2 µg/ml) and goat anti-
rabbit Alexa488 (2 µg/ml) and nuclei were stained with TO-PRO-3 (Invitrogen-Molecular 
Probes). Normal overview pictures and movies were made on a Leica DMIL microscope 
equipped with a Leica camera. Confocal images were made on a Leica SP2 AOBS confocal 





microscope. All images were processed with ImageJ 1.43M (NIH, USA) and Adobe 
Photoshop 7.01.  
 
[3H]-Leucine incorporation assay 
Cells were grown in 12-well plates and subsequently starved for 24 hours in DMEM 
containing starvation medium lacking FCS. As described previously 28, L-[4,5-3H]Leucine was 
added to all wells and cells were cultured for an additional 20 hours either in the presence or 
absence of 10 nM endothelin-1 (ET-1) or 50µM phenylephrine (PE). Subsequently, cells 
were washed twice with 1 ml PBS, followed by incubation for 1 hour at 4° C in 1 ml cold 5% 
TCA was. After one wash with TCA solution and one wash with PBS, proteins were 
solubilised with 0.5 ml 0.5M NaOH for 1 hour at RT and transferred to scintillation tubes 
containing 5 ml Ultima Gold XR scintillation liquid. The amount of radioactivity (CPM) was 




BI 2536 treatment of primary cardiomyocyte cultures 
Primary cardiomyocytes were isolated from neonatal rat hearts and were cultured for three 
days in the presence of serum in order to adapt to the medium and allow any cardiomyocytes 
that have not reached end-stage differentiation to fulfil a last round of division. Subsequently, 
cardiomyocyte cultures were treated with the Plk1 inhibitor BI 2536 or were left untreated. As 
shown in Figure 1A, addition of 100 nM BI 2536, a concentration shown to arrest most cell 
lines maximally 4, resulted in a small increase in rounded up cells within 24 hours, indicative 
for a mitotic arrest. Further analysis by immunofluorescence microscopy confirmed that these 
rounded cells were in mitosis and contained predominantly monopolar spindles with 
condensed mitotic chromosomes (Figure 1B and data not shown). This is similar to what has 
been shown for cancer cell lines. Co-staining with troponin T, a cardiomyocyte specific 
marker revealed that the arrested cells were not cardiomyocytes and cardiomyocytes all 
showed normal interphase morphology (Figure 1B). To further confirm this, FACS analysis 
was performed using phospho-Histone H3 as a mitotic marker and α-actinin as a 
cardiomyocyte marker. In the control culture almost all cells were phospho-Histone H3 
negative, and hence in interphase Figure 1C-D. Moreover, a significant proportion of cells 
were α-actinin negative, indicating the presence of non-cardiomyocytes. This relative high 
level of these cells is most likely a result of the three days cultivation without inhibitors. 







Histone H3 positive and these were almost all α-actinin negative (Figure 1C-D). This shows 
that cardiomyocytes were not sensitive to BI 2536 and that predominantly the non-




Figure 1. Effect of BI 2536 on neonatal rat cardiomyocytes 
Neonatal rat cardiomyocytes were cultured for three days before 100 nM BI 2536, or DMSO as control, 
was added. A. Light microscopy pictures of control and 24 hours BI 2536 treated cultures. B. 
Immunofluorescence microscopy pictures of BI 2536 treated cells stained with anti-troponinT (red) and 
anti-α-tubulin (green). In the middle a mitotic cell is shown with monopolar spindle devoid of troponin T 
staining. Scale bar is 10 µM. C. FACS analysis of 24 hours treated and untreated cells stained with anti-
α-actinin and anti-phospho-Histone H3. Four regions are selected and marked as follow: C-I = 
cardiomyocytes in interphase, C-M = cardiomyocytes in mitosis, F-I = fibroblasts in interphase, F-M = 
fibroblasts in mitosis. D. Quantification of FACS profiles of control and 24 hours BI 2536 (BI) treated cells 
stained like in C. Dark grey bars indicate the percentage interphase cells and light grey bars indicate the 





























BI 2536 does not affect cardiomyocyte function and cellular growth 
(hypertrophy) 
Next we addressed if cardiomyocyte function could be affected by BI 2536. We first 
examined the beating frequency of these cells by video imaging (data not shown). The 
beating frequency in BI 2536 treated cultures was similar to control cultures. Also β-
adrenergic stimulation by isoproteronol was still normal in BI 2536 treated cells (data not 
shown). Even after two weeks incubation cardiomyocyte beating was still evident, indicating 
that BI 2536 does not show apparent interference with this major cardiomyocyte function. 
Primary neonatal cardiomyocyte cultures are predominantly used as a model for 
cardiac hypertrophy. After two days culture of cardiomyocytes cells were treated with or 
without BI 2536 for 24 hours followed with a similar incubation in starvation medium. 
Thereafter cells were treated with the hypertrophy inducing stimuli endothelin-1 (ET-1) or 
phenylephrine (PE) in the presence of [3H]Leucine. After 24 hours cells were harvested and 
the amount of [3H]Leucine incorporation into protein was determined. As shown in Figure 2A 
ET-1 strongly increased [3H]Leucine incorporation in cardiomyocytes and similar results were 




Figure 2. Effect of BI 2536 on hypertrophy induction in neonatal rat cardiomyocytes 
Cardiomyocyte cultures were grown as before with or without 100 nM BI 2536 and subsequently serum 
starved in the presence or absence of BI 2536. A. Effect of treatment with the hypertrophy inducing 
hormone ET-1 on cellular growth ([3H]-Leucine incorporation) in the presence or absence of BI. [3H]-
Leucine incorporation into cellular proteins was determined by liquid scintillation counting. Values are 
relative to the respective non-treated cultures and error bars depict standard deviations (n=3). B. 
Analysis of ANP gene expression by real-time PCR in cultures treated with or without ET-1 in the 
presence or absence of BI 2536. Levels are corrected for expression of the cyclophilin A housekeeping 
gene. Error bars depict standard deviations (n=3). 
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indicating that BI 2536 did not interfere with growth induction. The apparent stronger effect in 
the BI 2536 cultures, is a result of decreased fibroblast numbers in these cultures (see also 
below and Figure 3). To further corroborate this we also investigated ANP gene expression, 
which is a marker for the hypertrophic response and is expressed in cardiomyocytes only. As 
shown in Figure 2B, ANP expression was similarly up regulated in ET-1 treated cell cultures 
with and without BI 2536. Together, these results show that BI 2536 does not affect 
proliferation independent growth inducing responses. 
 
Not all non-cardiomyocytes can be removed by BI 2536 treatment 
The above results showed no apparent interference of cardiomyocytes function in the 
presence of BI 2536. Next we wanted to know if proliferating cells (>95% fibroblasts) in these 
cultures could be reduced by BI 2536 treatment. We included a mitotic shake-off to remove 
most mitotic cells before FACS analysis. As shown in Figure 3A, 24 hours BI 2536 treatment 
could already significantly reduce fibroblasts, resulting in a concomitant relative increase in 
the percentage of cardiomyocytes. This relative increase was further confirmed by the 
increase of troponin T expression, a cardiomyocytes specific marker, in these cultures 




Figure 3. BI 2536 reduces fibroblast numbers in cardiomyocyte cultures.  
Cardiomyocyte cultures were grown as before with or without 100 nM BI 2536. A. The percentage 
cardiomyocytes and cardiac fibroblasts were determined by FACS analysis, using anti-α-actinin staining. 
Before harvest mitotic cells were removed by shake off. Light gray bars indicate fibroblasts, dark grey 
bars show the percentage cardiomyocytes. B. After 24 hours treatment RNA was isolated from cells and 
real time PCR was performed with primers against cardiac troponin T to determine the expression level 
of this cardiomyocyte specific gene, providing an indirect measure for the number of cardiomyocytes. 
Error bars depict standard deviations (n=3). C. Same as in B, but with primers against periostin, a 
marker for cardiac fibroblasts.  
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cultures. This further confirmed that only non-cardiomyocytes, predominantly fibroblasts, 
were affected in these cultures. As shown in Figure 3A, prolonged incubation with BI could 
further lower the percentage of fibroblasts in these cultures. Nevertheless, even after 72 
hours, still about 20% non-cardiomyocytes were present as determined by FACS analysis. 
This is surprising since these cells can perform 2-3 rounds of cell division within this time 
period (cycling time 28 hours).  This suggests that not all proliferating cells are properly 
targeted by BI 2536.   
 
BI 2536 induces mitotic arrest of primary cardiac fibroblasts 
The contaminating cells in our cardiomyocyte cultures consisted predominantly of cardiac 
fibroblasts (>95%, data not shown). These cells are easily enriched by preplating and were 
subsequently used to test the effect of BI 2536 specifically on these primary proliferating cells. 
Since not all cells appeared to arrest with BI 2536 (Figure 3A), we analysed the 
concentration dependency. Using FACS analysis we determined the number of cells that 
arrested within 24 hours treatment with different BI 2536 concentrations.  This dose response 
curve revealed that primary fibroblast arrest was maximal at a dose of 100 nM and the IC50 
value was approximately 43 nM (Figure 4A). Not all cells did, however, arrest and a 
maximum of approximately 50% was observed at concentration of 100 nM and higher. The 
arrest of cardiac fibroblasts after 24 hours treatment with 100 nM BI 2536 was also clearly 
evident by the strong increase of rounded up cells (Figure 4B). Immunofluorescence 
microscopy confirmed the typical monopolar arrest of these cells, in contrast to the mostly 
bipolar mitotic cells in the control culture (Figure 4B). With HeLa cells an IC50 of only 9 nM 
was observed (Figure 4A), confirming previous results with these cells, and the maximal 
percentage of arrested cells was around 63%. At these low concentrations no effects were 
observed on neonatal rat cardiac fibroblast, showing that these cells are less sensitive. We 
also tested human primary HUVEC cells which arrested with an (IC50 of 30 nM), indicating 
that different cell types show different sensitivities.  
 
BI 2536 temporarily arrests primary cardiac fibroblasts 
To further corroborate the effect on primary fibroblasts, we also analysed the effect of BI 
2536 in time. As shown in Figure 5A, 24 hours after treatment with BI 2536 a clear mitotic 
population (phospho-Histone H3 positive) is present, which is absent in the control culture. In 
time, however, this population is diminishing, and a population of dead, low propidium iodide 
stained cells became apparent. Prolonged culturing of control cells did only provide a small 







hours about 41.5% of the cells were in mitosis and that 6.5% cells were dead. After 24 hours 
this has almost inverted with an average of 4.3% mitotic cells and 40.1% dead cells. 
Importantly, at this stage still about 55.1% of interphase cells were present. These cells were 
investigated by immunofluorescence microscopy and it turned out that more than 90% of 
these cells had multi- or micro-nucleated nuclei (Figure 5C), a clear sign of aberrant mitotic 
progression. We did not observe this micro-nucleation in cardiomyocytes treated with BI 
2536 (data not shown), which further supports that this only occurred in proliferating cells, 
most likely due to an escape of the BI 2536 induced mitotic arrest. This also clarifies why BI 





Figure 4. Effect of BI 2536 on rat cardiac fibroblasts 
Rat cardiac fibroblasts were cultured for two days before the indicated doses of BI 2536 or DMSO as a 
control were added. HeLa cells were cultured under identical conditions. A. Dose response curve of 
primary cardiac fibroblasts and HeLa cells. Cells were cultured for 24 hours with BI 2536 and 
subsequently fixed and stained with anti-phospho-Histone H3, as a mitotic marker, and then quantified 
by FACS analysis. Closed circles, HeLa cells; open circles, cardiac fibroblasts. B. Light microcopy 
pictures of control and 24 hours BI 2536 treated cardiac fibroblast cultures. C. Immunofluorescence 
microscopy pictures of same cells as in B, but stained with anti-α-tubulin (green) and the DNA stain TO-




In this paper we describe the effect of BI 2536 on primary cardiac fibroblasts and 
cardiomyocytes. We showed herein that BI 2536 does not generate adverse effects in 
cardiomyocytes, but does profoundly affect primary fibroblast. In particular, fibroblasts were  
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arrested in mitosis with monopolar spindles and died upon prolonged arrest. Nevertheless 
part of the cells escaped mitotic arrest, as was evident from the large number of multi- and 




Figure 5. BI 2536 temporarily arrests cardiac fibroblasts 
Rat cardiac fibroblasts were cultured for two days before 100 nM BI 2536 or DMSO as control were 
added. Cells were subsequently analysed at different time points. A. FACS analysis of cells stained with 
anti-phospho-Histone H3 and propidium iodide. In the upper panel the control cells are shown and in the 
lower panel the BI 2536 treated cells. The different regions are marked as follow: I is interphase, M is 
mitosis and D denotes dead cells. B. Quantification of FACS profiles, as shown in A (n=3). Dark grey bar 
depict interphase cells, light grey bar depicts mitotic cells and white bar depicts dead cells. C. 
Immunofluorescence pictures of remaining interphase cells after 24 hours culture in the presence or 
absence of BI 2536. Cells were stained with anti-α-tubulin (green) and the DNA stain TO-PRO-3 (blue). 
































potential concern for its use and will limit the potential of Plk1 inhibitors for enrichment of 
differentiated cells for cell therapy. As far as we know, this is the first analysis of the effects of 
BI 2536 on both primary and differentiated cells. 
BI 2536 did not appear to affect the function of differentiated cells, as tested here 
using neonatal cardiomyocytes. No apparent morphological changes were observed and 
cardiomyocyte beating continued in the presence of BI 2536. Even after 4 weeks incubation 
with BI 2536 these cells continued normal beating (data not shown). Despite the fact that 
these cells cannot proliferate anymore, cardiomyocytes can still increase in size, and 
cardiomyocyte hypertrophy is one of the hallmarks of heart failure 29, 30. We therefore also 
evaluated the effect of BI 2536 on the hypertrophic response to phenylephrine and 
endothelin-1 in vitro. As shown here cardiomyocyte hypertrophy could be induced in the 
presence of BI 2536, and even appeared more pronounced than in the absence of BI 2536. 
The latter was most likely due to the reduction in fibroblasts in these BI 2536 treated cultures, 
resulting in lower background values. Thus, BI 2536 specifically blocks proliferation, but does 
not seem to affect proliferation-independent hypertrophic cell growth of cardiomyocytes.  
  Our results with BI 2536 showed a clear mitotic arrest of primary rat fibroblast with 
monopolar spindles, which is similar to the observed arrest of cancer cells. This is in contrast 
to anti-Plk1 microinjection study in human fibroblasts, which showed predominantly a G2 
phase-like arrest phenotype in primary cells, despite a clear mitotic arrest in cancer (HeLa) 
cells 11. Although we cannot exclude a possible G2 delay in these cells, the major phenotype 
is mitotic arrest. A similar observation was made with primary human (HUVEC) cells, 
indicating that this is not due to species differences (data not shown).  Plk1 siRNA based 
studies have suggested that Plk1 depletion did not affect normal cells or was much less 
effective in normal cells, as compared to cancer cells 12, 13. Although higher concentrations of 
BI 2536 were required to arrest primary rat fibroblasts as compared to HeLa cels, we 
observed a clear mitotic arrest indicating that also in normal cells Plk1 is essential for proper 
mitotic progression. The absence of a mitotic phenotype with siRNA studies suggests, 
therefore, that depletion was not sufficient to generate this phenotype in normal cells.  
Like in cancer cells arrested by Plk1 depletion or inhibition, we also observed cell 
death in primary cells following the mitotic arrest. In addition, however, we observed multi- 
and micro-nucleated cells in primary fibroblast populations treated with BI 2536. After 24 
hours even more than 90% of the present interphase fibroblasts showed this multi- and 
micro-nucleation phenotype. This phenotype is a clear sign of abnormal mitotic progression, 
indicating that a substantial number of primary fibroblasts escaped the mitotic arrest. This 
effect has not been reported for cancer cells treated with BI 2536 4. This is surprising since it 
is often thought that, in contrast to normal cells, cancer cells might have a partially impaired 





mitotic checkpoint, explaining chromosome instability in the latter 31. Thus, it appears that 
cancer cells die more efficiently upon Plk1 inhibition, as compared to normal cells. The latter 
is in line with a recent study describing the effects of microtubule drugs on cancer and normal 
cells 32. In this paper, the authors described that cancer cells are more susceptible to cell 
death upon mitotic arrest by the microtubule stabilizing agent taxol, as compared to normal 
cells. Our results suggest that this might be similar for Plk1 mediated mitotic arrests, 
suggesting that this is a general spindle checkpoint associated phenomenon. Although this is 
beneficial for the elimination of cancer cells, it begs the question what will happen with 
normal cells that have become aneuploid as a result of BI 2536 treatment. Since aneuploidy 
is a hallmark of most solid tumors 33 this could be a concern.  
 Altogether, our results show that Plk1 inhibition by BI 2536 treatment has no 
obvious effects on differentiated cardiomyocytes. It also, shows that whereas BI 2536 can 
inhibit proliferation it does not affect proliferation independent cell growth. Plk1 inhibition by 
BI 2536 resulted in mitotic arrest of primary fibroblast followed either by cell death or 
checkpoint slippage and aneuploidy. The latter will hamper the potential use of Plk1 inhibitors 
for the depletion of proliferating cells from differentiated cell cultures for cell therapy and 
might be a concern in general. Nevertheless, as shown here, it could be useful in cell 
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Heart failure (HF) is a complex disease involving multiple changes including cardiomyocyte 
hypertrophy (growth). Here we performed a set of screens in different HF and hypertrophy 
models to identify differentially expressed genes associated with HF and/or hypertrophy. 
Hypertensive Ren2 rats and animals with post-MI HF were used as in vivo HF models and 
neonatal rat cardiomyocytes treated with hypertrophy inducing hormones phenylephrine, 
endothelin-1 and isoproterenol were used as in vitro models. This combined approach 
revealed a robust set of genes that were differentially expressed both in vitro and in vivo. 
This included known genes like NPPA (ANP), Xirp2 and FHL1, but also novel genes not 
previously associated with hypertrophy/HF. Amongst these are PTGIS, AKIP1 and Dhrs7c, 
which could constitute interesting targets for further investigations. We also identified a 
number of in vivo specific genes and these appeared to be enriched for fibrosis, wounding 
and stress responses. Therefore a number of novel genes within this in vivo specific list could 
be related to fibroblasts or other non-cardiomyocytes present in the heart. We also observed 
strong differences between the two HF rat models. For example CA3 and WISP2 were 
strongly upregulated in post-MI HF, but not in Ren2 rats, indicative for etiology specific 
differences. Together these results show that combining multiple models, both in vivo and in 
vitro, can provide a robust set of hypertrophy/HF associated genes. Moreover it provides 
insight in the differences between the different etiology models and neurohormonal effects. 
 
  








Heart failure (HF) is often the end-result of a number of cardiovascular diseases, including 
myocardial infarction, hypertension and valve abnormalities. To maintain sufficient cardiac 
output under these conditions the heart adapts to these changes, a process called cardiac 
remodeling 13. Cardiac fibrosis and hypertrophy are the two major processes driving cardiac 
remodeling.  
The initiating stimuli for cardiac hypertrophy can be broadly separated into 
biomechanical or stretch-sensitive mechanisms and neurohormonal mechanisms 12. The 
latter include amongst others catecholamines (adrenaline and noradrenaline) and endothelin-
1, which bind to specific plasmamembrane receptors and activate intracellular signaling 
pathways 12. Although these signaling pathways are inherently complex and involve 
significant cross-talk, the common outcome, besides hormone specific effects, is the 
induction of cardiomyocyte growth. This involves direct activation of protein synthesis and 
altered gene expression. A hallmark of cardiac hypertrophy is the activation of the so called 
fetal gene program, which includes the re-expression of a number of fetal genes 24. Important 
examples are atrial natriuretic peptide (ANP, NPPA) and brain natriuretic peptide (BNP, 
NPPB), and the latter is commonly used as a HF plasma marker 16. 
 Numerous global gene expression studies have been performed on human or 
animal heart tissue to identify genes that are differentially expressed during HF. Usually gene 
expression is compared between opposing pairs, such as non-failing vs. failing hearts and 
once it is performed it is essential to narrow down the large candidate gene lists. The gene 
sets of different studies only partly overlap, because of diversity in disease severity, 
etiologies and microarray platforms 1. Meta-analysis of gene expression studies has therefore 
identified some HF genes, including ANP, BNP, ACTC1 (α cardiac actin), POSTN (periostin), 
but also revealed that most genes were only found in a limited set of studies 1. Gene array 
studies have also been performed on cultured primary neonatal rat cardiomyocytes 3, 5, 10, 14, 
which are used as a general in vitro cardiomyocyte hypertrophy model. Compared to in vivo 
studies it has the advantage that it involves a relatively pure cell population, that there are no 
systemic effects present in the background, and that conditions can be well controlled. 
However, in vitro observations do not necessarily reflect in vivo changes. Also these studies 
generated large candidate lists that were not easily comparable, because of different 
platforms, time durations and stimuli used 3, 5, 10, 14.  
As far as we know, no direct comparisons have been made between hyper-
trophy/HF induced in vitro and in vivo gene expression changes. This combination could 







We therefore treated neonatal rat ventricular cardiomyocytes (NRVCs) with hypertrophy 
stimulating agents phenylephrine (α-adrenergic), isoproterenol (β-adrenergic) and 
endothelin-1. In addition we used two different HF models, namely Ren2 rats that 
overexpress mouse renin generating hypertension and resulting in HF and we used a rat 
post-myocardial infarction (MI) model. Our results show overlap between the models and 
identified some potential novel hypertrophy/HF associated genes. In addition interesting 
differences between the different models and conditions were observed.  
 
Materials and methods 
 
Reagents and chemicals 
Cell culture medium and serum were obtained from Lonza Benelux B.V. (Breda, The 
Netherlands), penicillin-streptomycin and trypsin were from Invitrogen (The Netherlands). L-
[4,5-3H]-Leucine (37 MBq/ml; 5.85 TBq/mmol) was from GE Healthcare Europe (Diemen, 
Belgium) and Ultima Gold XR scintillation liquid was from Perkin Elmer (Groningen, The 
Netherlands). Unless otherwise stated all chemicals were purchased at the highest possible 
grade from Sigma-Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). 
 
Cardiomyocyte isolation and culturing 
NRVCs were isolated from the cardiac ventricles of one to three days old Sprague-Dawley 
(SD) pups after decapitation, as previously described 19. In short, hearts were removed from 
the thoracic cavity and ventricular tissue fragments were repeatedly treated with 2 mg/ml 
trypsin to release the cells. To remove non-cardiomyocytes, isolated cells were preplated in 
cell culture dishes in 50 ml MEM medium with 5% FCS for 45 min. During this period, most 
non-cardiomyocytes (mainly fibroblasts) attached to the dish (Greiner Bio-One), whereas 
cardiomyocytes remained in solution. The cardiomyocytes were subsequently transferred to 
separate tissue culture dishes and allowed to attach. NRVCs were cultured at 37° C under 5% 
CO2 in DMEM medium, supplemented with 10% FCS and penicillin-streptomycin (100 IU/ml 
and 100 µg/ml, respectively), as described previously 19. For experiments in which cells were 
treated with hypertrophy inducing agents, cells were first serum starved for 24 hours. Cells 
were then treated 24 hours with either 50 µM phenylephrine (PE), 10 µM isoproterenol (Iso) 
or 10 nM endothelin-1 (ET-1).  
 
Animal experiments 
We used male TGR(mRen2)27 (Ren2) rats that were homozygous for the expression of the  






mouse renin (Ren)-2 transgene (Max Delbrück Center for Molecular Medicine, Berlin-Buch, 
Germany) 7, 17. SD rats were used as controls. Animals were fed ad libitum. Ren2 rats and 
control rats were sacrificed at 13 weeks of age 26. In parallel, HF was induced in SD rats by 
permanent ligation of the left coronary artery to produce a MI 18. Anesthetic agents used: 
isoflurane (5% induction, 2.5% maintenance with oxygen) and proper anesthesia was 
confirmed by reflex analysis and by heart rate monitoring. Analgesics used: buprenorphine 
0.04 mg/kg, every 8 hours for 3 days. Control rats underwent a sham operation. Nine weeks 
after MI animals were sacrificed. All animals were sacrificed under general anesthesia, as 
described above, by heart removal. Myocardial tissues from all groups were snap frozen for 
molecular analyses. All animal studies were conducted in accordance with the NIH Guide for 
the Care and Use of Laboratory Animals and were submitted to, and approved by, the 
Committee for Animal Experiments of the University of Groningen. 
 
Quantitative Real-Time PCR 
Relative gene expression of ANP, cyclophilin A and GAPDH was determined by quantitative 
real time PCR (RT-PCR) on a Bio-Rad CFX384 real time system using SYBR Green dye, as 
described before 23. Gene expression was determined by correcting for reference gene 
values (cyclophilin A or GAPDH), and the calculated values were expressed relative to the 
control group per experiment. Primer sequences of ANP and cyclophilin A have been 
described before 19. GAPDH sequences are: GAPDH-forward-catcaagaaggtggtgaagc; 
GAPDH-reverse-accaccctgttgctgtag. 
 
L-[4,5-3H]-Leucine incorporation assay 
Cardiomyocytes were grown in 12-well plates and subsequently starved for 24 hours in 
DMEM containing starvation medium lacking FCS. Subsequently, L-[4,5-3H]-Leucine was 
added to all wells either in the presence or absence of 50 µM PE, 10 µM Iso or 10 nM ET-1. 
Cells were cultured for an additional 24 hours and radioactivity incorporation was determined 
as described before 19. 
 
Microarray Sample Preparation and Analysis 
Total RNA from the cells or tissue was extracted using the Nucleospin RNA II kit (Macherey-
Nagel, Düren, Germany). RNA quality was checked using the Agilent 2100 Bioanalyzer™ 
and subsequently prepared for microarray analysis using the standard Illumina® 
TotalPrep™-96 RNA Amplification Protocol (Ambion, Inc.). Samples were exponentially 







cRNA using the Illumina® TotalPrep™-96 RNA Amplification Kit (Ambion, Inc.). This final 
cRNA was evaluated and the quality, concentration and size of the reaction productions were 
measured using the Agilent RNA 6000 Nano Kit (Agilent). Illumina RatRef-12 Beadchips 
were used for microarray analysis. Chips were scanned using the BeadXpress Reader™ 
(Illumina). Beadstudio™ Illumina was used to import the raw data and remove any 
background noise. Data was converted to standard format and exported for use in Agilent 
Genespring GX™ (version 11.0, Agilent). We used Genespring to perform quantile 
normalization on each individual well and further analysis of the data. The MIAME standard 
for microarray data was followed and all data were submitted to the CIBEX database 
(accession codes: CBX250 and CBX251). 
 
Statistical analysis 
All data are expressed as mean±SEM. The differences between two groups were determined 
by a Student’s t test. Comparisons between more than two groups of data were assessed by 





In vivo rat HF models for gene expression analysis 
To identify genes that are differentially expressed during hypertrophy and HF development, 
we used a combined in vitro/in vivo gene array approach. For the in vivo analysis two 
different animal HF models were compared to their respective control groups. One group 
consisted of transgenic Ren2 rats (n=4), which overexpress mouse renin, resulting in 
hypertension and consequently HF development 7, 17. These animals were compared to SD 
rats, their genetic wild type background (n=5). In the other rat model a MI was induced by 
permanent ligation of the left coronary. These animals were sacrificed nine weeks post-MI 
together with the sham operated animals (n=5, 4). As determined by the heart weight-to body 
weight (HW/BW) ratios, significant cardiac hypertrophy was observed in both the Ren2 rats 
(5.06±0.05 vs. 3.29±0.11 mg/g in the control, p<0.05) and also in the post-MI rats a clear 
increase (4.34±0.52 vs. 3.65±0.40 mg/g in the control) was apparent. Moreover, cardiac ANP 
expression, a marker for HF, was significantly increased in the Ren2 and post-MI rats (Figure 
1A, 1B). Hemodynamic data further confirmed HF formation in these animals (data not 
shown).  
 






In vitro cardiomyocyte hypertrophy models 
The in vitro hypertrophy model consisted of cultures of primary isolated NRVCs , which were 
exposed to three different hypertrophy inducing agents (n=4 in each group, PE n=3). As 
determined by L-[4,5-3H]-leucine incorporation (protein synthesis), treatment with PE and ET-
1 generated a strong hypertrophic response, whereas Iso induced a modest increase (Figure 
1C). A similar trend was observed for ANP gene expression, which was strongly elevated 
after PE and ET-1 treatment and only modestly elevated after Iso treatment (Figure 1D). 
Together, this shows that these treatments trigger hypertrophy and fetal gene expression in 
cardiomyocytes in vitro. 
 
 
Figure 1. Confirmation of the in vivo and in vitro hypertrophy/HF models 
A. RT-PCR on cDNA from Ren2 rats (n=5) with HF and as a control on SD rats (n=4 for each group). 
ANP expression is shown relative to GAPDH levels. B. RT-PCR on cDNA from post-MI HF and sham 
operated rats (n=4 for each group). ANP expression is shown relative to GAPDH levels. C. Primary 
neonatal rat cardiomyocytes were cultured for 24 hours in serum free medium and subsequently 
stimulated with PE, Iso or ET1. After 24 hours stimulation in the presence of L-[4,5-3H]-Leucine the 
radioactive incorporation in cellular protein was analyzed by liquid scintillation counting. Values are 
relative to the respective non-treated cultures (n=4 for each group). D. ANP expression in the different 
cardiomyocyte cultures was determined by RT-PCR and corrected for cyclophilin A expression (n=4).  
SD=Sprague Dawley rats, Ren2=TGRm(Ren2)27 rats, MI= myocardial infarction, cont=control, ET-




































Gene array analysis animal models 
Whole genome gene expression in the cardiac animal samples and of the cardiomyocyte 
cultures was analyzed using Illumina RatRef-12 Beadchip arrays. Only those genes that 
showed a significant 1.5 fold change in gene expression (p<0.05) as compared to their 
respective control groups were selected. This yielded 159 differentially expressed genes in 
the Ren2 group and 254 differentially expressed genes in the MI group. Subsequently, the 
overlap in both HF groups was analyzed, yielding only a small set of 58 genes (16%) that 
were similarly up- or downregulated in both groups (Figure 2A). Since genes that are just 
above selection threshold in one group, might be missed in the other group this 
representation could give a biased view. Therefore we also analyzed whether the top 10 up- 
and downregulated genes in the Ren2 and MI groups showed a similar distribution. As can 
be depicted from Table 1 this is indeed the case. Within this top ten several common HF 
markers, including periostin (POSTN) 22 and ANP 16, were similarly upregulated in both 
animal groups.  It is remarkable, however, that the two strongest upregulated genes in the MI 
group, CA3 (Carbonic anhydrase 3) and WISP2 (Wnt1 inducible signaling pathway protein 1), 
were not upregulated in the Ren2 group. Vice versa the two strongest upregulated genes in 
 
 
Figure 2. Venn diagrams of the number of differentially expressed genes identified in the different 
groups 
A. Differential gene expression in different groups was determined as described in the text. A. Differen-
tially expressed genes in Ren2 and post-MI animals as compared to their respective controls. B. 
Differentially expressed genes identified after stimulation for 24 hours with PE, Iso or ET-1. C. Differen-
tially expressed genes present in at least in two in vitro models were compared with the differentially 
expressed genes present in at least one in vitro model. An overlap of 62 genes was identified. 
Ren2= TGRm(Ren2)27 rats, MI=myocardial infarction, ET-1=endothelin-1, Iso=isoproterenol, 
PE=phenylephrine.  
A                                                     B C 
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the Ren2 group, KCNE1 (Potassium Channel, voltage-gated, ISK related subfamily, member 
1) and RGD1562305 (SBSN, Suprabasin), were not upregulated in the MI group. The full 
gene tables are presented in Supplemental gene list 1. 
 
 In vitro cardiomyocyte hypertrophy models 
Whole genome gene expression of the hypertrophy induced cardiomyocyte cultures was 
compared to the untreated culture group. This revealed that 415, 170 and 321 genes were 
differentially expressed after PE, ET-1 and Iso treatment respectively (p<0.05, >1.5 fold 
difference) (Figure 2B). Thus both adrenergic stimuli (PE and Iso) gave a stronger 
hypertrophic effect than ET-1, even though hypertrophy development with Iso was less 
pronounced, as compared to ET-1 (Figure 1C). Comparison of these data sets showed a 
common overlap of 71 genes. A list of the 10 most upregulated genes present in at least two 
conditions is presented in Table 2. Most of the top ten genes were upregulated by all three 
stimuli and include known cardiac disease genes, like Xirp2, Scn3b and ACTC1. Although 
HF markers, like ANP and BNP, were not present in this top these are present in the full 
gene list (Supplemental gene list 2). It is remarkable that the strongest upregulated gene, 
PNOC (Prepronociceptin) was specific for PE and Iso stimulation. In addition, the potassium 
voltage gated channel, KCND2 was upregulated only in ET-1 treated cells and the aldoketo 
reductase gene AKR1B8 was specific for Iso stimulation. Most downregulated genes were 
specific for adrenergic stimulation (Iso and/or PE), including the strongly downregulated short 
chain dehydrogenase/reductase gene Dhrs7c. Only one gene of the top 10 genes was 
downregulated by all three stimuli, ANGPT2 (angiopoietin 2), a protein involved in vascular 
remodeling 9.   
 
Comparison of the in vitro and in vivo data sets 
To compare the in vitro data with the in vivo data all differentially in vitro expressed genes 
that were present in at least 2 conditions (253 genes) were compared with all differentially in 
vivo expressed genes (355 genes). This yielded a set of 62 genes differentially expressed in 
at least two in vitro and one in vivo model (Figure 2C). Within the group of 62 genes, 
established hypertrophy/HF markers like ANP and BNP and a promising new HF marker 
LGALS3 (galectin-3) were present 6, 8. Based on the average fold change gene expression 
we made a list of the top 10 up- and downregulated genes found in at least 2 in vitro models 
and one in vivo model (Table 3). In this list, a number of known HF markers and cardiac 
disease genes are present, like ANP, XIRP2, CSRP2, FHL1, TIMP1 and LGALS3. However, 
it also includes novel upregulated genes like AKIP1 (also termed BCA3 or C11Orf17), PTGIS 







62 genes there are 9 genes that are regulated in an opposite manner in vitro as compared to 
in vivo (Supplemental gene list 3). We also identified a large number of genes that showed 
differential expression in vitro, but not in vivo and vice versa (Table 4). 
 
Table 1. Top ten genes with highest up- or downregulation in at least one in vivo model (1.5 fold, p<0.05) 
Gene Genbank 
Id Protein Regulation Ren2 MI 
CA3 54232 carbonic anhydrase III Up - 47.71 
WISP2 29576 WNT1 inducible signaling pathway protein 2 
Up 
- 28.79 
LTBP2 59106 latent transforming growth factor beta binding protein 2 Up 8.64 24.93 
KCNE1 25471 potassium voltage-gated channel, Isk-related family, member 1 
Up 24.67 - 
RGD1562305 292793 suprabasin Up 16.09 - 
THBS4 29220 thrombospondin 4 Up - 14.15 
POSTN 361945 periostin, osteoblast specific factor Up 8.82 13.50 
SDPR 316384 serum deprivation response Up 11.17 - 
PRG4 289104 proteoglycan 4 Up - 10.88 
ANP 24602 atrial natriuretic peptide Up 9.39 5.96 
RT1-A1 24973 RT1 class Ia, locus A1 Down -20.52 - 
RGD1561381 498340 similar to microsomal glutathione S-transferase 3 
Down 
-20.29 - 
RPS9 81772 ribosomal protein S9 Down -19.53 - 
LOC498989 498989 similar to Ab2-143 Down -13.85 - 
RGD1564649 367102 similar to 40S ribosomal protein S9 
Down 
-11.94 - 
USMG5 171069 up-regulated during skeletal 
muscle growth 5 homolog 
Down 
-11.78 - 
VEGFB 89811 vascular endothelial growth factor B 
Down 
-9.52 - 
MRPL17 171061 mitochondrial ribosomal protein L17 
Down 
-7.39 - 
SLC3a1 29484 solute carrier family 3, member 1 Down -4.24 - 
RPS9 81772 ribosomal protein S9 Down -4.06 - 
 – means absence of up/or down regulation. Ren2 (n=4), SD=Sprague Dawley (n=5), MI=myocardial 
infarction (n=5) and sham (n=4). 
 






Table 2. Top ten genes with highest up- or downregulation in at least one in vitro model (>1.5 fold, 
p<0.05) 
Gene   Genbank 
 Id Protein Regulation ET-1 Iso PE 
PNOC 25516 prepronociceptin Up - 28.35 42.36 
WFDC1 171112 WAP four-disulfide core domain 1 Up 3.89 5.30 11.05 
Scn3b 245956 sodium channel, voltage-gated, type III, beta Up 4.37 4.98 6.82 
Xirp2 497771 xin actin-binding repeat 
containing 2 Up 4.14 3.29 5.85 
INHA 24504 inhibin alpha Up 2.13 4.48 5.62 
ACTC1 29275 actin, alpha, cardiac muscle 1 Up 3.37 3.37 5.05 
RGD1560242 499334 similar to RIKEN cDNA 1700028P14 Up 1.83 3.69 4.84 
AKR1B8 286921 aldoketo reductase family 1, 
member B8 Up - 4.55 - 
KCND2 65180 potassium voltage-gated channel, Shal-related subfamily, member 2 Up 4.31 - - 
RND1 362993 Rho family GTPase 1 Up 2.06 3.91 4.25 
Dhrs7c 287411 dehydrogenase/reductase (SDR family) member 7C Down - -20.18 -4.12 
LOC50106
6 501066 WITHDRAWN Down - -6.31 - 
CXCL11 305263 chemokine (C-X-C motif) ligand 11 Down - -5.56 -3.17 
Asb11 302666 ankyrin repeat and SOCS box 
containing 11 Down - -4.81 -2.04 
PTPRR 94202 protein tyrosine phosphatase, 
receptor type, R Down - -4,79 -4,58 
Angpt2 89805 angiopoietin 2 Down -1.92 -4,01 -4,66 
CITED1 64466 
Cbp/p300-interacting 
transactivator with Glu/Asp-rich 
carboxy-terminal domain 1 
Down - -3.75 -1.96 
V-ATPase S1 361875 ATPase, H+ transporting, lysoso-
mal accessory protein 1 Down - -3.66 - 
RXRG 83574 retinoid X receptor gamma Down - -3.47 -3.12 
CXCL10 245920 chemokine (C-X-C motif) ligand 10 Down - -3.30 - 
 – means absence of up/or down regulation. Control (n=4), ET-1=endothelin-1 (n=4), Iso=isoproterenol 








Gene ontology analysis 
Finally, we performed gene ontology (GO) analysis using Genetrail with the different data 
sets.  In most data sets no specific enrichment of gene clusters with particular functions was 
obtained, but for the in vitro and in vivo specific data sets some highly significant scores were 
 
 
Table 3. Top ten genes with highest up- or downregulation in at least two in vitro models and at least 
one in vivo model (1.5 fold, p<0.05) 
Gene Genbank  Id Protein Regulation 
Mean 
score 
Xirp2 497771 xin actin-binding repeat containing 2 Up 3.97 
ANP 24602 atrial natriuretic peptide Up 3.95 
CSRP2 29317 cysteine and glycine-rich protein 2 Up 2.77 
PTGIS 25527 prostaglandin I2 (prostacyclin) synthase Up 2.66 
C11Orf17 361624 A kinase (PRKA) interacting protein 1 Up 2.48 
FHL1 25177 four and a half LIM domains 1 Up 2.44 
TIMP1 116510 tissue inhibitor of metalloproteinase 1 Up 2.42 
TNFRSF12a 302965 tumor necrosis factor receptor superfamily, 
member 12A Up 2.13 
AVPI1 171386 arginine vasopressin-induced 1 Up 2.11 
LGALS3 83781 lectin, galactoside-binding, soluble, 3 Up 1.99 
ENAH 360891 enabled homolog (Drosophila) Up 1.98 
Dhrs7c 287411 dehydrogenase/reductase (SDR family) 
member 7C Down -6.21 
CXCL11 305236 chemokine (C-X-C motif) ligand 11 Down -2.92 
RXRG 83574 retinoid X receptor gamma Down -2.37 
SLC4a1ap 298805 solute carrier family 4 (anion exchanger), 
member 1, adaptor protein Down -2.06 
SLC2a4 25139 solute carrier family 2 (facilitated glucose transporter), member 4 Down -1.95 
LRP16 246233 MACRO domain containing 1 Down -1.71 
PINK1 298575 PTEN induced putative kinase 1 Down -1.68 
CABC1 360887 chaperone, ABC1 activity of bc1 complex like (S. pombe) Down -1.66 
HADHSC 113965 hydroxyacyl-CoA dehydrogenase Down -1.63 
ECH1 64526 enoyl CoA hydratase 1, peroxisomal Down -1.60 
The mean score is the average fold up- or down regulation. 






obtained. The in vivo specific genes were enriched for extracellular matrix (p=4.4x10-7), 
wounding (p=2.0x10-6) and stress (p=2.6x10-5) (Table 5). This included the highly expressed 
genes LTBP, POSTN, fibronectin (FN1) and LOXL1. In contrast the in vitro specific genes 
were enriched for genes involved in terpenoid backbone (p=8.9x10-11) and steroid 
biosynthesis (p=1.4x10-6) pathways (Table 5). Especially in PE and ET-1 treated cells nearly 
all genes of these pathways, which together are involved in sterol, cholesterol and steroid 
biosynthesis, were upregulated (see Supplemental figure S1). 
 
Table 4. In vitro and in vivo specific genes 
In vitro only In vivo only 
Gene Entrez  Id Regulation Gene Entrez Id Regulation 
PNOC 25516 Up LTBP2 59106 Up 
SCN3b 245956 Up POSTN 361945 Up 
INHA 24504 Up NUPR1 113900 Up 
ACTC1 29275 Up FN1 25661 Up 
RGD1560242 499334 Up SERPINE2 29366 Up 
RND1 362993 Up LOXL1 315714 Up 
MYBPC2 292879 Up MGC72614 310540 Up 
IFIT1 294090 Up MFAP5 362429 Up 
YIP1B 364147 Up CTGF 64032 Up 
SLPI 84386 Up ANXA2 56611 Up 
ANGPT2 89805 Down TXN2 79462 Down 
PTPRR 94202 Down ACAT1 25014 Down 
ASB11 302666 Down PFKM 65152 Down 
LOC191574 191574 Down ALDH5a1 291133 Down 
Adhfe1 362474 Down LDHD 307858 Down 
CXCL13 498335 Down ISOC1 364879 Down 
RGD1562717 363767 Down NDE1 83836 Down 
SMOC2 292401 Down SESn1 294518 Down 
CITED1 64466 Down GOT2 25721 Down 
PTN 24942 Down RGD1565358 314759 Down 
Top ten genes with highest up- or downregulation specific for at least two in vitro conditions (left half) or 









Cardiomyocyte growth (hypertrophy) is one of the hallmarks of HF development 12, 13. Here 
we investigated gene expression profiles of in vitro cultured cardiomyocytes treated with 
hypertrophy inducing agents (PE, ET-1 and Iso) and in vivo HF models (hypertensive Ren2 
rats and post-MI rats). This approach yielded large data sets of differentially expressed 
genes. By overlapping them a concise set of genes, including numerous known HF markers, 
were obtained. Interestingly, this set also included a number of interesting genes not linked to 
hypertrophy/HF before. Analysis of differential gene expression in cardiomyocytes stimulated 
with hypertrophy inducing agents and in two rat HF models generated large lists of 
differentially expressed genes. By combining these expression data sets we obtained a 
concise list of 62 differentially expressed genes. This list included most known HF markers, 
including ANP, BNP, TIMP1, FHL1, LGALS3 (Table 3 and Supplementary gene list 3), 
indicating that this is a powerful approach to identify differentially expressed genes that are 
specifically linked to hypertrophy and HF development. This list also comprised genes that 
have recently been linked to cardiac remodeling, like TNFRSF12a (also termed Fn14) 4, 
indicating that this approach could uncover new HF genes. In fact this list contained a 
number of genes regulated in a similar fashion that have previously not been linked to 
hypertrophy and HF development. This list includes PTGIS, a gene for which myocardial 
infarction, hypertension and stroke associated polymorphisms have been identified by GWAS  
 
Table 5. GGO analysis of in vitro and in vivo specific genes 
Specificity Category P value Genes 
In vivo 
Extracellular matrix 4.4x10-7 Ltbp2, FN1, Loxl1, Col3a1, Serpine2, Mgp, Ctgf, Anxa2 
Wounding 2.0x10-6 FN1, Nupr1, Col3a1, Serpine2, Serping1, Anxa2, Anxa1, Aif1, C1s 
Stress response 2.6x10-5 
FN1, Nupr1, Col3a1, Serpine2, 
Serping1, Ctgf, Anxa2, Anxa1, Aif1, 
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Dhcr24, Idi1, Hmgcs1, Cyp51, Dhcr7, 
Fdps, Fdft1, Pmvk, Mvd, Cln8 




Dhcr24, Idi1, Hmgcs1, Cyp51, Dhcr7, 
Fdps, Fdft1, Pmvk, Mvd, Cln8, Por 
 






studies 21, AKIP1, an adaptor protein in the PKA-NFkB pathways 11, 27 and the short chain 
dehydrogenase/reductase Dhrs7c (downregulated). Our inventory could therefore be an 
important starting point for the investigation of novel genes associated with HF. 
Our investigations also revealed clear differences between in vitro and in vivo 
experiments. GGO analysis showed a strong enrichment for extracellular matrix, wounding 
and stress specific genes in the in vivo list. This included the highly expressed genes LTBP, 
POSTN, FN1 and LOXL1. These genes are predominantly expressed by fibroblasts or other 
non-cardiomyocytes in the heart and explains the absence in the in vitro cardiomyocyte 
experiments. This list is therefore of particular interest since it contains many differentially 
expressed HF genes that are specific for non-cardiomyocytes. Further analysis of 
uncharacterized genes present in this list, like MGC72614 (FAM198B), could therefore be a 
rewarding opportunity. GGO analysis also revealed a strong enrichment of genes involved in 
the terpenoid and steroid biosynthesis pathways that are specifically upregulated in vitro after 
hypertrophic stimulation. Since these pathways are essential for the novo cholesterol 
synthesis, it might suggest that there is an increased requirement for cholesterol during 
hypertrophic growth of cardiomyocytes.   
Also marked differences were observed within the in vivo models. Carbonic 
anhydrase III (CA3) for example was almost 50 fold induced in the post-MI group, but not in 
the Ren2 group. CA3 is the major cytosolic carbonic anhydrase in muscle and liver tissue 28. 
It probably functions to protect proteins from oxidation catalyzed by iron-containing 
degradation products of hemoglobin and myoglobin and/or regulating intracellular pH 28, 25. 
Although not essential under normal conditions, it might become important in certain 
diseased states 15. It could be envisioned that acidification and iron containing degradation 
products might be a major problem in post-MI hearts, explaining the strong upregulation in 
one (post-MI), but not the other (Ren2) model. The absence of induction in the Ren2 model 
indicates that fibrotic processes in post-MI and Ren2 animals are not similar. In the Ren2 
group suprabasin (RGD1562305) expression was specifically increased. This extracellular 
protein was originally suggested to play a role in striated epithelia 20, but was recently also 
shown to be strongly induced in muscle of exercised dogs 2. Together with our observation, 
this may suggest that suprabasin also plays a role in heart and muscle function under stress 
related conditions. Whether the absence in the post-MI HF group suggests etiologic 
specificity is not known, but it might be rewarding to investigate plasma levels of this secreted 
protein in different HF groups. 
Several features of the experiments are important in the interpretation of the present 
data. First we used neonatal rat cardiomyocytes for in vitro hypertrophy and compared these 







and in vivo data could be related to the age of the cells, neonatal versus adult. We made this 
choice because neonatal rat cardiomyocytes are used as an established model for in vitro 
cardiomyocyte hypertrophy. Some differences could be related to the timing of the 
experiments. In vitro hypertrophy induction only lasted 24 hours and therefore some of the 
changes might be related to early responses in contrast to the in vivo experiments. As 
pointed out for KCNE1, some of the effects might also be temporal or related to the severity 
of HF and hence be present in one, but not the other group. As with most screens we also 
missed some known HF markers, like SERCA, indicating that although comprehensive the 
generated lists are not complete. Except for ANP we did not confirm the microarray data by 
direct, specific quantitation of mRNAs or proteins in the heart or cardiomyocytes. 
In conclusion, we have identified a comprehensive set of genes that are differentially 
expressed in in vitro cardiomyocyte models for hypertrophy and in animal HF models. This 
list includes a large number of genes known to be associated with HF, as well as potential 
new targets, like AKIP1, for future analysis. Furthermore, we have identified a large number 
of genes that appear to be specific for particular conditions. This stresses again that we have 
to be careful with extrapolations from one to another model or condition. These datasets 
should prove invaluable for a further analysis of cardiac diseases in particular pathological 
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SFigure 1. Terpenoid and steroid biosynthesis pathways 







Gene list S1. Differentially expressed genes identified in in vivo post-MI HF and Ren2 rat models   
        (fold change >1.5 and p<0.05) 
 
Gene Genbank ID Protein Regulation MI Ren2 
Ltbp2 59106 latent transforming growth factor beta binding protein 2 up 24.93 8.64 
Postn 361945 periostin, osteoblast specific factor up 13.50 8.82 
Nppa 24602 natriuretic peptide precursor type A up 5.96 9.39 
Pap 24618 pancreatitis-associated protein up 4.59 5.91 
Nupr1 113900 nuclear protein 1 up 5.09 5.06 
Col8a1 304021 procollagen, type VIII, alpha 1 up 6.99 3.14 
Fn1 25661 fibronectin 1 up 5.69 2.60 
Serpine2 29366 serine (or cysteine) proteinase inhibitor, 
clade E, member 2 up 3.35 4.45 
Timp1 116510 tissue inhibitor of metallopeptidase 1 up 4.50 2.78 
RGD1306959 361624 similar to C11orf17 protein up 2.58 4.42 
Loxl1 315714 lysyl oxidase-like 1 up 4.51 2.33 
Col3a1 84032 procollagen, type III, alpha 1 up 3.35 3.26 
Pi16 294312 protease inhibitor 16 up 3.50 2.67 
MGC72614 310540 hypothetical LOC310540 up 2.55 3.17 
Mfap5 362429 microfibrillar associated protein 5 up 3.94 1.71 
Ifitm1 293618 interferon induced transmembrane protein 1 up 2.73 2.79 
Maoa 29253 monoamine oxidase A up 2.33 2.91 
Lgals3 83781 lectin, galactose binding, soluble 3 up 2.99 2.08 
Ctgf 64032 connective tissue growth factor up 2.83 2.11 
Anxa2 56611 annexin A2 up 2.83 1.86 
Prss23 308807 protease, serine, 23 up 2.51 2.07 
Serping1 295703 serine (or cysteine) peptidase inhibitor, 
clade G, member 1 up 2.92 1.64 
Mgp 25333 matrix Gla protein up 2.96 1.60 
Aif1 29427 allograft inflammatory factor 1 up 2.39 1.94 
Col14a1 314981 procollagen, type XIV, alpha 1 up 2.40 1.86 
Anxa1 25380 annexin A1 up 2.41 1.62 
Gpx3 64317 glutathione peroxidase 3 up 2.23 1.75 
Ecm1 116662 extracellular matrix protein 1 up 2.05 1.90 
Wbp5 294067 WW domain binding protein 5 up 1.78 2.13 
Cd248 293669 CD248 antigen, endosialin up 2.22 1.55 
Fuca 24375 fucosidase, alpha-L- 1, tissue up 1.56 2.19 






Gene Genbank ID Protein Regulation MI Ren2 
Scpep1 114861 serine carboxypeptidase 1 up 2.07 1.56 
Sulf2 311642 sulfatase 2 up 2.02 1.61 
C1s 192262 complement component 1, s 
subcomponent up 1.96 1.52 
Grn 29143 granulin up 1.72 1.66 
Vim 81818 vimentin up 1.85 1.52 
Ccnd1 58919 cyclin D1 up 1.70 1.60 
Aldh1a1 24188 aldehyde dehydrogenase family 1, 
member A1 up 1.53 1.69 
Ankrd1 27064 ankyrin repeat domain 1 up 1.55 1.67 
Prnp 24686 prion protein up 1.60 1.61 
Txn2 79462 thioredoxin 2 down -1.76 -3.23 
Aqp7 29171 aquaporin 7 down -2.77 -1.57 
Boll 302920 bol, boule-like down -1.98 -2.24 
Slc2a4 25139 solute carrier family 2 (facilitated glucose transporter), member 4 down -2.11 -2.07 
Acat1 25014 acetyl-coenzyme A acetyltransferase 1 down -1.85 -2.32 
Lrp16 246233 LRP16 protein down -2.20 -1.77 
Pfkm 65152 phosphofructokinase, muscle down -2.13 -1.62 
Aldh5a1 291133 aldehyde dehydrogenase family 5, 
subfamily A1, transcript variant 3 down -1.68 -2.06 
Hrc 292905 histidine rich calcium binding protein down -1.95 -1.68 
Ldhd 307858 lactate dehydrogenase D down -2.06 -1.53 
Rxrg 83574 retinoid X receptor gamma down -1.96 -1.59 
Isoc1 364879 isochorismatase domain containing 1 down -1.51 -1.89 
Nde1 83836 nuclear distribution gene E homolog 1 down -1.51 -1.88 
Mlycd 85239 malonyl-CoA decarboxylase down -1.85 -1.53 
Sesn1 294518 sestrin 1 down -1.54 -1.62 
Got2 25721 glutamate oxaloacetate transaminase 2, 
mitochondrial down -1.55 -1.52 
RGD1565358 314759 similar to genes associated with retinoid-IFN-induced mortality 19 down -1.52 -1.52 














Gene list S2. Differentially expressed genes identified in in vitro cardiomyocyte cultures treated with PE, 
Iso or ET-1 (fold change >1.5 and p<0.05) 
 
Gene Genebank ID Protein Regulation PE ET-1 Iso 
Wfdc1 171112 WAP four-disulfide core domain 1 up 11.05 3.89 5.30 
Scn3b 245956 sodium channel, voltage-gated, type III, beta up 6.82 4.37 4.98 
LOC497771 497771 hypothetical gene supported by NM_201989 up 5.85 4.14 3.29 
Inha 24504 inhibin alpha up 5.62 2.13 4.48 
Actc1 29275 actin alpha  cardiac 1 up 5.05 3.37 3.37 
RGD1560242 499334 similar to RIKEN cDNA 1700028P14 up 4.84 1.83 3.69 
Rnd1 362993 Rho family GTPase 1 up 4.25 2.06 3.91 
Ptgis 25527 prostaglandin I2 (prostacyclin) 
synthase up 4.10 2.28 2.77 
Fhl1 25177 four and a half LIM domains 1, transcript variant 2, mRNA. up 3.57 2.43 2.29 
Mybpc2 292879 myosin binding protein C, fast-type up 3.47 2.11 3.41 
Igsf9 304982 immunoglobulin superfamily, 
member 9 up 3.39 1.72 2.66 
RGD1310766 364147 similar to YIP1B up 3.19 2.09 2.96 
Hbegf 25433 heparin-binding EGF-like growth factor up 3.18 1.97 2.26 
Tnfrsf12a 302965 tumor necrosis factor receptor 
superfamily, member 12a up 2.99 1.86 2.21 
Irf6 364081 interferon regulatory factor 6 up 2.86 1.69 2.39 




coupled receptor 7 
up 2.67 1.74 2.73 
Cspg4 81651 chondroitin sulfate proteoglycan 4 up 2.59 1.94 1.70 
Lamc2 192362 lamimin, gamma 2 up 2.55 1.85 1.73 
Acta1 29437 actin, alpha 1, skeletal muscle up 2.50 2.06 1.99 
Gloxd1 313521 glyoxalase domain containing 1 up 2.49 2.26 2.48 
G7c 309611 G7c protein up 2.49 1.67 3.27 
Cyp51 25427 cytochrome P450, subfamily 51 up 2.48 1.89 1.55 
Avpi1 171386 arginine vasopressin-induced 1 up 2.47 1.96 1.98 
Hspb3 78951 heat shock 27kDa protein 3 up 2.44 2.01 2.20 
Olfm1 93667 olfactomedin 1 up 2.37 1.58 1.66 
Adprhl1 290880 ADP-ribosylhydrolase like 1 up 2.36 1.84 1.96 
Slc16a3 80878 
solute carrier family 16 
(monocarboxylic acid transporters), 
member 3 
up 2.34 1.82 1.79 






Gene Genebank ID Protein Regulation PE ET-1 Iso 
Enah 360891 enabled homolog (Drosophila) up 2.30 1.62 1.93 
Idi1 89784 isopentenyl-diphosphate delta isomerase up 2.30 1.90 1.66 
Pdlim5 64353 PDZ and LIM domain 5 up 2.27 1.66 1.50 
Lrrc8c 289443 leucine rich repeat containing 8 family, member C up 2.17 1.54 1.77 
Csrp3 117505 cysteine and glycine-rich protein 3 up 2.12 1.70 1.96 
Dnajb5 313811 DnaJ (Hsp40) homolog, subfamily B, member 5 up 2.07 1.52 1.97 
LOC365025 365025 similar to alpha tubulin subunit up 2.03 1.64 1.71 
Dhcr24 298298 24-dehydrocholesterol reductase up 2.03 2.04 1.89 
RGD1306959 361624 similar to C11orf17 protein up 2.03 1.64 1.71 
Itgb1bp2 317258 integrin beta 1 binding protein 2 up 2.03 1.76 1.81 
Tuba4a 316531 tubulin, alpha 4A up 2.02 1.75 1.86 
RGD1311552 311355 similar to KIAA0377-like protein , transcript variant 4 up 1.98 1.53 1.66 
Pib5pa 171088 phosphatidylinositol (4,5) bisphosphate 5-phosphatase, A up 1.96 1.74 2.04 
Dmn 308709 desmuslin, transcript variant 2 up 1.95 1.70 1.82 
Mgst2 295037 microsomal glutathione S-transferase 2 up 1.95 1.72 1.67 
Por 29441 P450 (cytochrome) oxidoreductase up 1.84 1.53 1.59 
Abra 286965 actin-binding Rho activating protein up 1.84 1.55 1.54 
Gnao 50664 guanine nucleotide binding protein, 
alpha o up 1.70 1.58 1.70 
Angpt2 89805 angiopoietin 2 down -4.66 -1.92 -4.01 
LOC191574 191574 3-alpha-hydroxysteroid dehydrogenase down -3.18 -2.45 -2.19 
RGD1562717 363767 similar to ABI gene family, member 3 (NESH) binding protein down -2.87 -2.46 -1.67 
Smoc2 292401 SPARC related modular calcium binding 2 , transcript variant 2 down -2.75 -1.89 -2.15 
RGD1311203 305472 similar to HGFL protein down -2.75 -1.60 -1.65 
Cdkn1c 246060 
cyclin-dependent kinase inhibitor 
1C (P57) , transcript variant 1, 
mRNA. 
down -2.56 -1.56 -1.65 
Irf7 293624 interferon regulatory factor 7 down -2.48 -1.78 -1.76 
Agtr1a 24180 angiotensin II receptor, type 1 (AT1A) down -2.44 -1.59 -1.84 
Prp2 293634 proline-rich protein PRP2 down -2.41 -2.09 -1.71 
CXCL13 498335 similar to Small inducible cytokine B13 precursor down -2.40 -2.85 -1.99 
Eln 25043 elastin down -2.11 -1.64 -1.74 
RGD1560587 316539 similar to Eph receptor A4 down -2.00 -1.65 -1.80 







Gene Genebank ID Protein Regulation PE ET-1 Iso 
Kcnk3 29553 potassium channel, subfamily K, 
member 3 down -1.87 -1.73 -1.97 
Gpm6a 306439 glycoprotein m6a down -1.86 -1.62 -1.58 
Ech1 64526 enoyl coenzyme A hydratase 1, peroxisomal down -1.86 -1.59 -1.60 
Fmod 64507 fibromodulin down -1.84 -1.56 -1.55 
Hamp 84604 hepcidin antimicrobial peptide down -1.79 -1.65 -1.69 
RGD1559432 498937 RGD1559432 down -1.76 -1.64 -1.65 
Mllt3 114510 myeloid/lymphoid or mixed-lineage leukemia,translocated to, 3 down -1.75 -1.53 -1.56 
Ptgds 25526 prostaglandin D2 synthase down -1.73 -1.54 -1.53 
Npy 24604 neuropeptide Y down -1.68 -2.34 -2.10 
Plagl1 25157 pleiomorphic adenoma gene-like 1 down -1.54 -1.72 -1.58 
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Aims Although cardiac diseases account for the highest mortality and morbidity rates in 
Western society, there is still a considerable lack in our knowledge of genes that contribute to 
cardiac (dys)function. Here we screened for gene expression profiles correlated to heart 
failure. Methods and results By expression profiling we identified a novel gene, termed 
DHRS7c, which was significantly downregulated by adrenergic stimulation and in heart 
failure models. Dhrs7c is a short chain dehydrogenase/reductase (SDR) and localized to the 
endo/sarcoplasmatic reticulum.  Dhrs7c is strongly conserved in vertebrates, and mRNA and 
protein expression levels were highest in heart and skeletal muscle followed by skin, but was 
not detectable in other organs. In vitro, both α- and β-adrenergic stimulation repressed 
Dhrs7c expression in neonatal cardiomyocytes and this could be mimicked by the direct 
activation of PKC and adenylate cyclase, the respective intracellular targets of these 
hormones. In contrast, endothelin-1, which also provoked strong hypertrophy development in 
vitro, did not repress Dhrs7c expression. The latter suggests adrenergic specificity and 
indicates that downregulation is not a prerequisite for hypertrophy development. Also in vivo 
adrenergic stimulation could downregulate Dhrs7c expression. Finally, we confirmed that 
expression was also downregulated in two different models of failure and importantly, also in 
biopsies from human heart failure patients. Conclusion Our results show that the expression 
of Dhrs7c, a novel endo/sarcoplasmatic reticulum localized SDR, is inversely correlated with 
adrenergic stimulation and heart failure development. 







Heart failure (HF) is the final common pathway of most cardiovascular diseases. HF 
develops gradually as a result of pathological stress factors acting on the heart of which the 
most common causes are myocardial infarction (MI) and hypertension. Sustained myocardial 
stress is associated with increased ventricle wall stress and causes the heart to react with a 
compensatory program involving fibrosis 1 and cardiomyocyte growth (hypertrophy) 2, 3. 
Although initially this is believed to be beneficial, on the long term this leads to cardiac 
remodelling and decompensation, resulting in decreased pump function and HF.  
The course of HF development is inherently complex and involves multiple factors, 
including biomechanical, (neuro)hormonal and para- and autocrine activation. Neurohumoral 
factors including, catecholamines (adrenaline, noraderenaline), endothelin-1, angiotensin II 
and IGF-I have all been shown to generate cardiomyocyte hypertrophy in vitro 3. This 
suggests that these factors activate overlapping gene programs, even though they activate 
different cellular pathways and have different effects on cardiomyocyte function.  Examples 
of HF markers that are upregulated by these pathways are atrial and brain natriuretic 
peptides (ANP and BNP). These factors belong to the so called fetal gene program and have 
clinical relevance 4, 5. Identification of additional genes controlled by these pathways would 
therefore be of interest since their expression might be associated to hypertrophy and/or HF 
development.  
Here we performed gene expression screens on cultured rat cardiomyocytes 
activated with adrenergic stimuli phenylephrine (α-adrenergic) and isoproterenol (β-
adrenergic). The combined analysis revealed a novel gene, DHRS7c, encoding a short chain 
dehydrogenase/reductase (SDR), which is downregulated by adrenergic stimulation both in 
vitro and in vivo. Moreover, we confirm the down-regulation in multiple rat HF models and in 
human HF patient biopsies.  
 
Materials and Methods 
 
Reagents and chemicals 
Polyclonal anti-Dhrs7c antibody was generated as described in the supplemental materials 
and methods. Mouse monoclonal anti-α-actinin antibody EA53 was from Sigma-Aldrich 
Chemie B.V.. Rabbit polyclonal anti-troponin (ab9332) and anti-myc antibody were from 
Abcam (Cambridge, MA, USA). Rhodamine-phalloidin, Mitotracker red FM, Complex III 







monoclonal myc 9E10 and anti-GAPDH were from Santa cruz, mouse monoclonal anti-KDEL 
was from Stressgen. Goat anti-GM130 was a kind gift from Prof. F. Barr. L-[4,5-3H]Leucine 
(37 MBq/ml; 5.85 TBq/mmol) was from GE Healthcare Europe (Diemen, Belgium). Unless 
otherwise stated all chemicals were purchased at the highest possible grade from Sigma-
Aldrich Chemie B.V. (Zwijndrecht, The Netherlands).  
 
Neonatal rat cardiac myocyte and fibroblast isolation 
Neonatal rat ventricle cardiomyocytes (NRVCs) were isolated from the cardiac ventricles of 
one to three days old Sprague-Dawley (SD) pups after decapitation, as previously described 
6
. NRVCs were cultured at 37ºC under 5% CO2 in DMEM medium, supplemented with 10% 
FCS and penicillin-streptomycin (100 IU/ml and 100 µg/ml, respectively), as described 
previously 6. For experiments in which cells were treated with hypertrophy inducing agents 
cells were first serum starved for 24 hours. Cells were then treated 24 hours with either 
phenylephrine (PE), isoproterenol (Iso) or endothelin-1 (ET-1).  
 
Animal experiments 
Continuous Iso/PE infusion (20mg/kg/day Iso and 20 mg/kg/day PE) was performed with 
C57Bl/6j mice of 3 to 4 months old. As a control saline infusion was used. Infusion was 
mediated using osmotic minipumps (Alzet, Maastricht, The Netherlands, Model 2002), which 
were inserted subcutaneously in the left flank of the mice. Mice were anesthetized with 
isoflurane (2% in O2). Mice were sacrificed 2 or 7 days after insertion of the pumps and 
bodyweight and heart weight were determined. As a HF model we used male 
TGR(mRen2)27 (Ren2) rats that were homozygous for the expression of the mouse renin 
(Ren)-2 transgene (Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany) 7, 8. 
SD rats were used as controls. Animals were fed ad libitum. Ren2 rats and control rats were 
sacrificed at 13 weeks of age 9. As a separate model, HF was induced in Munich Wistar 
Fromter (MWF) rats by permanent ligation of the left coronary artery to produce a myocardial 
infarction (MI). Anaesthetic agents used: isoflurane (5% induction, 2.5% maintenance with 
oxygen) and proper anaesthesia was confirmed by reflex analysis and by heart rate 
monitoring. Analgesics used: buprenorphine 0.04 mg/kg, every 8 hours for 3 days. Control 
MWF rats underwent a sham operation. Twelve weeks after MI animals were sacrificed. All 
animals were sacrificed under anaesthesia, as described above, by heart removal. 
Myocardial tissues from all groups were snap frozen for molecular analyses. All animal 
studies were conducted in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals and approved by the Committee for Animal Experiments of the University 
of Groningen. 





[3H]-Leucine incorporation assay 
Cells were grown in 12-well plates (Greiner Bio-One) and subsequently starved for 24 hours 
in DMEM containing starvation medium lacking FCS. Subsequently, L-[4,5-3H]Leucine was 
added to all wells either in the presence or absence of 50 µM PE, 10 µM Iso or 10 nM ET-1. 
Cells were cultured for an additional 20 hours and radioactivity incorporation was determined 
as described before 6.  
 
Microarray Sample Preparation and Analysis 
Total RNA from the cells or tissue was extracted using the Nucleospin RNA II kit (Macherey-
Nagel, Düren, Germany). RNA quality was checked using the Agilent 2100 Bioanalyzer™ 
and subsequently prepared for microarray analysis using the standard Illumina® 
TotalPrep™-96 RNA Amplification Protocol (Ambion, Inc.) Samples were exponentially 
amplified from a starting amount of 50 ng to a final amount of 1 µg purified biotin-labeled 
cRNA using the Illumina® TotalPrep™-96 RNA Amplification Kit (Ambion, Inc.). This final 
cRNA was evaluated and the quality, concentration and size of the reaction productions were 
measured using the Agilent RNA 6000 Nano Kit (Agilent). Illumina RatRef-12 Beadchips 
were used for microarray analysis. Chips were scanned using the BeadXpress Reader™ 
(Illumina). Beadstudio™ Illumina was used to import the raw data and remove any 
background noise. Data was converted to standard format and exported for use in Agilent 
Genespring GX™ (version 11.0, Agilent). We used Genespring to perform quantile 
normalization on each individual well and further analysis of the data.  
 
Cloning and adenoviral production 
Myc-tagged Dhrs7c adenovirus was constructed as described in the supplementary methods. 
Each NRVC culture was infected at an MOI of 50-100. Medium was changed 13 hours after 
infection. Microscopy were performed 24 hours after infection. 
 
Patients 
Patients were described previously 10. All patients had idiopathic dilated cardiomyopathy 
(DCM) with New York Heart Association (NYHA) class III-IV symptoms. Tissues from 
patients were obtained during cardiac catheterization by right ventricular endomyocardial 
biopsy. Control myocardial tissue from brain dead donors was harvested from non-failing, 
normal hearts which became available for cardiac transplantation. This protocol was 
approved by a local Ethics committee and all investigations were performed in accordance 







Quantitative real-time PCR, Western blotting and microscopy 
Standard methodology was applied see supplemental methods. 
 
Statistical analysis 
All data are expressed as mean±SEM. The differences between two groups were determined 
by a Student’s t test. Comparisons between more than two groups data were assessed by 





Identification of DHRS7c by expression profiling 
Using gene arrays we investigated differential gene expression in cultured primary neonatal 
rat cardiomyocytes that were stimulated for 24 hours with hypertrophy inducing agents 
phenylephrine (PE, α-adrenergic) and isoproterenol (Iso, β-adrenergic). This revealed 43 
differentially expressed genes common to both stimuli (SFigure 1A). Interestingly, the 
strongest downregulated gene appeared to be a gene with unknown function. This gene 
annotated as DHRS7c was downregulated about 20 fold in Iso treated cardiomyocytes and 
more than 4 fold in PE treated cells. Bioinformatics (NCBI Blast analysis) revealed that 
DHRS7c is a member of the classical short chain dehydrogenase/reductase (SDR) family 11  
and is conserved from fish to men (SFigure 1B).  
 
Dhrs7c localizes to the endo/sarcoplasmatic reticulum  
Based on the presence of an N-terminal signal sequence in Dhrs7c, this protein is predicted 
to localize to membranes. To investigate its particular localization, we made an adenoviral 
construct with Dhrs7c containing a C-terminal myc-tag. This protein was expressed in 
neonatal rat cardiomyocytes and its localization was determined by confocal immuno-
fluorescence microscopy. As shown in Figure 1A, myc-tagged Dhrs7c did not appear to 
localize to the plasma membrane, but was visible in intracellular structures, predominantly 
around the nucleus. The identity of these cells as cardiomyocytes was confirmed by α-actinin 
staining (SFigure 2). Co-staining with the golgi marker GM130 or with mitotracker, a 
mitochondrial marker, did show no or only partial (golgi) co-localization (Figure 1B). Co-
localization was, however, clearly observed with the endo/sarcoplasmatic reticulum (ER) 
marker KDEL, indicating that Dhrs7c is a novel ER protein (Figure 1B). To confirm that 





endogenous Dhrs7c also localized to the SR we performed subcellular fractionation of a rat 
heart. Using a self-generated polyclonal against Dhrs7c we could show that Dhrs7c protein 
was enriched in the microsomal/ER fraction in Figure 1C. Together, these results indicate 
that Dhrs7c is an ER associated protein in cardiomyocytes.  
 
Dhrs7c is not downregulated by ET-1 and hence this does not appear to 
be essential for hypertrophy development 
Next we wanted to confirm the potential relation between Dhrs7c downregulation, adrenergic 
stimulation and hypertrophy development. In addition to PE and Iso stimulation, hypertrophy 




Figure 1. Dhrs7c is an endo/sarcoplasmatic reticulum localized protein 
NRVCs were cultured in vitro and infected with recombinant adenovirus expressing myc-tagged Dhrs7c. 
A. After fixation and permeabilization myc-Dhrs7c cells were stained with anti-myc (green) for Dhrs7c 
and phalloidin (red) to stain the actin cytoskeleton. The merged picture at the right also contains TO-
PRO-3 stained nuclei (blue). Top row shows myc-Dhrs7c infected cells. Bottom row shows control 
infected cells (showing faint non specific nuclear staining). B. Cells were stained with anti-myc (green) 
and anti-KDEL (red) (top row), anti-myc (green) and anti-GM130 (red) (middle row) and anti-myc (green) 
and mitotracker (red) (bottom row). The merged pictures at the right with TO-PRO-3 stained. C. Different 
cellular fractions of a rat heart were isolated and probed by Western blotting with anti-Dhrs7c, anti-
Calnectin (ER marker) and anti-ComplexIII subunit Core2 (ComIII, mitochondrial marker). Mito=mito-
chondrial, ER=endo/sarcoplasmatic reticulum, and Cyto=cytosolic fraction. Bars indicate 10 µm. 








by 3H-Leucine incorporation, showing that PE and ET-1 strongly induced hypertrophy and 
that Iso gave a modest but significant induction of hypertrophy (Figure 2A). ANP expression 
showed the same pattern as 3H-Leucine incorporation (Figure 2B). DHRS7c mRNA 
expression, however, showed a different pattern, with the strongest downregulation in 
isoproterenol treated cells (~20 fold), followed by PE treated cells (~5 fold), whereas in ET-1 
treated cells the expression remained nearly constant (Figure 2C). At the protein level 
Dhrs7c could be detected in control and ET-1 treated cultures as a 34kda band, the predicted 
size of Dhrs7c (Figure 2D). This band was nearly absent in Iso and PE treated cultures 
(Figure 2D). Thus, Dhrs7c protein levels paralleled mRNA expression. Further investigation 
showed that the downregulation was concentration dependent with half maximal repression 
at 0.07 µM Iso and 12.2 µM PE (SFigure 3). Combined treatment with both compounds 
provided an additive effect with maximal downregulation and also dobutamine (β1-adrenergic) 
and clenbuterol (β2-adrenergic) provided clear downregulation, in contrast to tyramine, a 
non-adrenergic monoamine (SFigure 3 and data not shown). Direct activation of the 
downstream signaling components of the α- and β- adrenergic pathway, using PMA 
(activates PKC) and forskolin (activates adenylate cyclase), respectively, also resulted in 
profound repression of Dhrs7c (Figure 2E and 2F).  
We also investigated the effect of myc-tagged Dhrs7c overexpression in isolated 
neonatal cardiomyocytes. Although no apparent phenotype was observed under standard 
culturing conditions, profound cell death was observed after Iso treatment, but not with ET-1 
(Figure 2G). Overexpression was confirmed by Western blotting and concomittant siRNA 
could suppress overexpression and cell death, indicating that this is a Dhrs7c specific effect 
(SFigure 4). No increased caspase 3 cleavage was observed, suggesting that cell death was 
not mediated via apoptosis (data not shown).  
 
Dhrs7c is a vertebrate SDR with a heart, muscle and skin specific 
expression  
To further characterize DHRS7c, we next analyzed its tissue specific expression. RNA was 
isolated from different tissues of mouse and used for real-time PCR quantification of DHRS7c 
expression. As shown in Figure 3A, DHRS7c mRNA appeared to be highly expressed in 
heart and muscle, lower expression was observed in skin and in other tissues expression 
was virtually absent. At the protein level Dhrs7c was expressed in heart, muscle and skin, but 
not in other tissues (Figure 3B). This parallels our mRNA expression data; although in skin 
the RNA levels were somewhat lower as compared to heart and muscle. Similar results were 
obtained with rat tissues indicating that this specific expression is a conserved feature, at 





least in mammals (SFigure 5). Since cardiac tissue consists predominantly of 
cardiomyocytes and fibroblasts, we also separated cardiomyocytes and fibroblasts from 
neonatal rat hearts to analyse cell type specific expression. As shown in Figure 3C and 3D,  
 
 
Figure 2. Adrenergic stimulation downregulates Dhrs7c expression in neonatal rat cardiomyocytes in 
vitro. 
NRVCs were cultured for 24 hours in serum free medium and subsequently stimulated with PE, Iso or 
ET-1. After 24 hours stimulation cells were harvested for analysis. A. [3H]-Leucine incorporation in 
cellular protein was analysed to determine the hypertrophic effects of the different hormones. Values are 
relative to the respective non-treated cultures (n=3). B. ANP expression in the different cultures was 
determined by RT-PCR and corrected for cyclophilin A expression (n=9). C. DHRS7c expression in the 
different cultures was determined by RT-PCR and corrected for cyclophilin A expression (n=9). D. 
Representative Western blot of Dhrs7c protein expression in the different cultures. E. Similar as in C, but 
now Forskolin treated culteres were analysed (n=6). F. Similar as in C, but now PMA treated culteres 
were analysed (n=4). G. NRVCs were cultured in vitro and infected with recombinant adenovirus 
expressing myc-tagged Dhrs7c or as a control a GFP expressing virus. After 24 hours in serum free 
medium cells were either stimulated with Iso or ET-1 or left untreated for another 24 hours. Light 
microscopy pictures of myc-Dhrs7c expressing cells (top row) or control GFP transfected cells (bottom 
row) with the indicated treatments are shown.  * indicates p<0.05 as compared to control.  
















Dhrs7c RNA and protein expression were predominantly confined to cardiomyocytes in the 
heart. During this analysis we also observed that Dhrs7c protein expression was higher in 
adult hearts as compared to neonatal hearts (Figure 3E). 
 
Dhrs7c mRNA and protein level are downregulated in animal heart failure 
models  
Based on the profound downregulation of Dhrs7c in vitro by adrenergic stimulation we next 
investigated if adrenergic stimulation could also downregulate Dhrs7c in vivo. In vitro a 
combination of Iso/PE gave a maximal downregulation within two days. Therefore a 
combination of Iso/PE (20 mg/kg/day each) was provided to mice using osmotic minipumps 
and after 2 and 7 days treatment these mice were sacrificed. Within 2 days heart weight to 
body weight (HW/BW) significantly increased (from 4.75±0.16 mg/g to 6.14±0.43 mg/g, 
 
 
Figure 3. DHRS7c mRNA and protein expression is restricted to heart, muscle and skin.  
RNA and proteins were isolated from the indicated mouse organs, tissues or cells and used for RT-PCR 
or Western blot analysis. A. Bar diagram showing relative DHRS7c mRNA expression in different mouse 
tissues. Levels were measured in triplicate and corrected for GAPDH. B. Western blot analysis of Dhrs7c 
in different mouse tissues. As a loading control GAPDH is shown. C. DHRS7c mRNA in NRVCs and 
cardiac fibroblasts (n=4) corrected for cyclophilin A. D. Dhrs7c protein expression in NRVCs and cardiac 
fibroblasts. E. Dhrs7c protein expression in neonatal versus adult rat hearts. Abbreviations: He=Heart, 
Br=Brain, Lu=Lung, Li=Liver, Ki=Kidney, In=Intestine, Mu=Muscle, Ad=Adipose, Sk=skin, Sp=Spleen, 
Te=Testis, Ov=Ovary, CM=cardiomyo-cytes, Fibr=fibroblasts. 





p<0.05) as a result of cardiac hypertrophy development and also BNP expression was 
significantly induced (from 1.07±0.34 to 4.86±1.00, P<0.05). In these hearts Dhrs7c 
downregulation could be observed at the RNA and the protein level, although the latter was 
less pronounced (Figure 4A). After 7 days treatment these effects were, however, less clear 
and not significant at the protein level (Figure 4B), suggesting a temporal effect. 
 
Dhrs7c is downregulated in animal HF models 
Since adrenergic infusion is a rather artificial model, we were wondering whether Dhrs7c 
would also be downregulated in other disease models. In particular we analysed 
downregulation in Ren2 rats that overexpress mouse renin, generating hypertension resulting 
in HF development 7, 9. In Ren2 rats HF development was evident from the increased HW/BW 
ratio as compared to control animals (5.40±0.20 mg/g vs 3.30±0.08 mg/g, p<0.05). Moreover, 
in these Ren2 animals cardiac ANP expression, a marker for HF development, was strongly 





Figure 4. DHRS7c mRNA and protein expression are downregulated after adrenergic stimulation in vivo. 
Mice obtained a contiuous Iso/PE infusion (20 mg/kg/day of each) using osmotic minipumps for 2 or 7 
days. Cardiac gene and protein expression of Dhrs7c were subsequently determined. A. Cardiac 
DHRS7c gene expression after 2 days Iso/PE infusion (n=3 control, n=5 Iso/PE). B Same as A, but after 
7 days (n=6 control, n=3 Iso/PE). C. Dhrs7c protein  expression after 2 days Iso/PE infusion (n=7 control, 
n=5 Iso/PE). D Same as C, but after 7 days (n=6 control, n=4 Iso/PE). * indiates p<0.05 as compared to 
the control. 








animals and this was also true for the Dhrs7c protein levels (Figure 5A). Since myocardial 
infarction (MI) is one of the major causes of HF development we also analyzed Dhrs7c 
expression in a post-MI rat HF model. These animals had a mean infarct size of 46.9±2.5 %. 
Hypertrophy development was evident from the increased HW/BW ratio (5.30±0.30 mg/g vs 
3.41±0.10 mg/g in sham, p<0.05) and ANP expression was elevated (14.73±0.40 fold, 
p<0.05). Dhrs7c RNA and protein levels were significantly down regulated in the non-
infarcted hypertrophied areas in these post-MI animals, as compared to sham operated 
animals (Figure 5B).  
 
Dhrs7c protein level is downregulated in heart failure patients 
Finally, we investigated Dhrs7c protein expression in heart biopsies of patients with severe 
DCM and ischemic HF (NYHA class III and IV) 10. As compared to control biopsies, the 
expression of Dhrs7c was significantly downregulated in these patients (Figure 5C). Together, 




Figure 5. Dhrs7c is downregulated during heart failure. 
RNA and/or protein were isolated from heart tissue and used for RT-PCR or Western blot analysis. A. 
RT-PCR on cDNA from Ren2 (n=7) and control SD (n=6) rats. ANP (top panel) and DHRS7c (lower 
panel) expression is shown relative to GAPDH levels. B. Western blot analysis of Dhrs7c expression in 
the same Ren2 and SD heart samples. Representative blots are shown together with the quantified data 
(lower panel). C. Western blot analysis of heart tissue from post-MI HF and sham operated MWF. 
Representative blots are shown together with the quantified data (lower panel) (n=5 for both groups). D. 
Dhrs7c protein expression in heart biopsies from DCM (n=3) or ischemic heart disease (n=2) patients 
and as a control hearts from persons without heart disease (n=6). Representative blots are shown and 
the bottom panel shows the quantified data. * indicates p<0.05 as compared to control. MI=post-MI HF, 
DCM=dilated cardiomyopathy, Isch=ischemic heart disease. 
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In the present paper we describe the identification of a novel SDR, termed Dhrs7c, which is 
down-regulated in response to adrenergic stimulation. Dhrs7c is conserved in vertebrates 
and its restricted expression in heart, muscle and skin, suggests that it has tissue specific 
functions. In two HF models in rats with different etiology, Dhrs7c was downregulated at both 
the RNA and protein level. Importantly, downregulation was observed also in human heart 
biopsies of patients with DCM and ischemic HF.  
Using gene arrays we uncovered a novel short chain dehydrogenase/reductase, 
termed Dhrs7c, which was downregulated in cardiomyocytes after Iso and PE stimulation. 
Dhrs7c contains an N-terminal transmembrane domain and our microscopical analysis and 
subcellular fractionation showed that Dhrs7c localized to the endo/sarcoplasmatic reticulum 
in cardiomyocytes. This is common for many of the other SDR family members and also its 
closest homolog Dhrs7b has been suggested to localize to the endoplasmatic reticulum 12 .  
 In vitro, Dhrs7c expression was downregulated upon Iso and PE treatment (β- and 
α-adrenergic agonist respectively), but surprisingly not after ET-1 treatment, even though ET-
1 strongly induced hypertrophy and ANP expression, similar to PE. This indicates that 
Dhrs7c downregulation is not directly linked to hypertrophy and, moreover, that its 
downregulation is not a prerequisite for hypertrophy development. In contrast, Iso treatment 
only generated modest hypertrophy, but provided the strongest downregulation of Dhrs7c. 
Together, this suggests that downregulation might be linked to adrenergic stimulation, rather 
than to hypertrophy. This is further supported by the observations that activation of the 
downstream intracellular targets of these adrenergic pathways, adenylate cyclase (β-
adrenergic) and PKC (α-adrenergic), with respectively forskolin and PMA, also resulted in 
downregulation of DHRS7c expression. Moreover, other adrenergic stimuli like dobutamin 
(β1-receptor) and clenbuterol (β2-receptor) also generated profound downregulation, 
whereas tyramine, a monoamine that does not activate adrenergic pathways, did not 
generate any downregulation.   
Also in vivo Dhrs7c was downregulated by adrenergic stimulation, although this 
appeared to be a temporal effect. Two days after continued infusion of Iso/PE 
downregulation was stronger as compared to 7 days infusion. One possible explanation 
could be desensitizing of β-adrenergic signaling in the adult heart. This is a well-known 
phenomenon 13, 14  and also other genes like ICERI have shown to be temporal repressed in 
the heart by adrenergic stimulation 15. Interestingly, in two independent HF models 







that this also occurs in more general cardiac disease models. Finally, downregulation was 
observed in human HF patients, supporting the generalizability of our experimental findings 
and indicating that this might have clinical relevance, too. Whether the decrease in Dhrs7c in 
rat and human HF are associated with adrenergic signaling is not known, but moderate 
adrenergic stimulation may occur in our Ren2 transgenic model and post-MI HF 16 and 
enhanced adrenergic signaling in human HF is a hallmark of this disease. We also observed 
that in vitro stretching of cardiomyocytes could downregulate Dhrs7c expression, indicating 
that the regulation of Dhrs7c might be more complex and does not only depend on 
adrenergic signaling (data not shown).  
The identification of the regulatory transcription factors will be pivotal in 
understanding the regulation of Dhrs7c, but equally important will be the clarification of its 
biological function. So far, the only observed phenotype was cell death in overexpressing 
Dhrs7c cardiomyocytes treated with Iso. This indicates that downregulation could be 
important during adrenergic stimulation. The cause of cell death is not clear yet, but did not 
appear to be apoptotic. Although this suggests a prominent function for this 
dehydrogenase/reductase, it does not clarify its biological function. Most classic SDR family 
members, to which also Dhrs7c belongs, and which localize to the ER, are involved in 
steroid/sterol biosynthesis 11. Although heart specific steroid synthesis seems peculiar we like 
to note that recently also another heart specific gene, SRD5A2L2, potentially implicated in 
steroid synthesis has been identified 17. Nevertheless, other ER like functions cannot be 
excluded and identification of its substrates will be crucial in clarifying its function. 
In conclusion, using gene arrays we uncovered a novel short chain 
dehydrogenase/reductase that is downregulated in cardiomyocytes upon adrenergic 
stimulation and in experimental HF models. Our observation that also in human HF patients 
Dhrs7c expression is downregulated, clearly warrants further research in the regulation and 
function of this gene. We foresee that our recently initiated combined approach of 
biochemical and transgenic animal studies will soon shed light on the function of this 
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 Supplemental Materials and Methods 
 
Production of recombinant adenovirus 
To generate recombinant adenoviral vectors the ViraPower Adenovirus Expression System 
(Invitrogen) was used according to the manufacturer’s instructions. Full length mouse 
DHRS7c was first cloned into pcDNA4/TOP/myc-HisC,creating a C-terminal fusion with the 
myc tag. The whole expression cassette containing cytomegalovirus (CMV) promoter, 
DHRS7c-myc and BGH pA sequences was transferred to the shuttle vector pENTR4. Using 
LR clonase (Invitrogen) the whole cassette was subsequently recombined into the pAD/PL-
DEST adenoviral vector. For siRNA, the shuttle vector pENTR4/H1 was constructed by 
inserting the H1 promoter from the pTER+ siRNA vector. In addition an EGFP expression 
cassette was cloned into this vector in order to visualize infected cells. DHRS7c specific 
siRNA targeting oligo nucleotides and as a control GL2 (luciferase) oligo nucleotides were 
cloned into this vector. Subsequent recombination into pAD/PL-DEST adenoviral vector was 
performed. All constructs were verified by sequencing. Recombinant adenovirus was 
produced by transfecting adenoviral constructs into HEK 293A cells using Lipofectamine 
2000 (Invitrogen). The titer of adenovirus was assessed by the limiting-dilution method 
(Clontech Adenovirus rapid titer manual) using 5x105 cells per well HEK 293A cells plated on 
12-well plates (Greiner Bio-One). 
 
Production of polyclonal antibodies 
Polyclonal rabbit antiserum specific for Dhrs7c was generated against the unique C-terminal 
domain of Dhrs7c. A hexahistidine (His6) - tagged C-terminal fragment of mouse Dhrs7c (a.a. 
212-311) was expressed in Escherichia coli using the pQE30 expression vector (Qiagen) and 
subsequently purified using NiNTA agarose (Qiagen). This purified recombinant protein 
fragment was used for immunization of rabbits (Biogenes GmbH, Berlin, Germany). Dhrs7c 
specific antibody was isolated from the rabbit serum using the same recombinant Dhrs7c 
protein fragment covalently coupled to AminoLink Plus beads (Thermo Scientific). For 
Western blotting this purified antibody was used at a concentration of 0.5 µg/ml. 
 
Microscopy 
Cells were grown on coverslips coated with 1 µg/cm2 laminin (Millipore) for the indicated time 
periods and subsequently washed with PBS and fixed in paraformaldehyde solution for 10 
min at room temperature. After permeabilization with 0.5% Triton X100, antibody incubations 







were: mouse monoclonal anti-KDEL (1:100), anti-myc 9E10 (1:100), goat anti-GM130 
(1:1000) and rabbit anti-myc (1:2000). Secondary Alexa antibodies (Invitrogen, The 
Netherlands) were used at 2 µg/ml. Nuclei were stained with TO-PRO3. For mitotracker 
staining cells were incubated for 30 minutes with 250 nM mitotracker Red FM and 
subsequently fixed and processed as described above. Confocal images were made on a 
Leica SP2 AOBS confocal microscope. All images were processed with ImageJ 1.43M (NIH, 
USA) and Adobe Photoshop 7.01. Z-stack projections of the confocal images are shown. 
 
Quantitative Real-Time PCR 
Relative gene expression of DHRS7c, ANP, BNP, cyclophilin A and GAPDH was determined 
by quantitative real time PCR (RT-PCR) on a Bio-Rad CFX384 real time system using SYBR 
Green dye. Gene expression was determined by correcting for reference gene values 
(cyclophilin A or GAPDH), and the calculated values were expressed relative to the control 
group per experiment. Primer sequences can be found in Table S1.  
 
Western blotting 
NRVCs and tissues were homogenized in ice-cold RIPA (50 mM Tris pH 8.0, 1% nonidet P40, 
0.5% deoxycholate, 0.1% SDS, 150 mM NaCl) containing phosphatase inhibitor cocktail 1 
(Sigma), protease inhibitor (Roche), 1 mM phenylmethylsulfonyl fluoride (PMSF) and 15 mM 
NaVanadate for 30 min. Equal amounts of proteins were loaded on 12% polycrylamide gels. 
After electrophoresis, the gels were blotted onto nitrocellulose membranes. Membranes were 
then incubated with primary antibodies overnight at 4° C and signals were visualized with 





















Primers for real time PCR 
Name Species  Sequence 
DHRS7c  mouse Forward: GGAGAACAGGCCAGATTGTG 
  Reverse: CTCGGAGGCAGTCAAAGAAG 
 rat Forward: GGACGCCAACTACTTTGGAC 
  Reverse: GTCGAAGAAGCCCATGACAG 
GAPDH  mouse / rat  Forward: CATCAAGAAGGTGGTGAAGC 
  Reverse: ACCACCCTGTTGCTGTAG 
Cycolophilin A 
 





























DHRS7c Forward GAAGGATCCGTCGACATGGGGCTCATGGCTGTCCTG 
 Reverse GAACTCGAGCCCGGGCACCCTCTTCTGGGACATTGAGC 
siRNA primers 
GL2 Forward GATCCCCGTACGCGGAATACTTCGATTCAAGAGATCGAAGTATTCCGCGTACGTTTTTGGAAA 
 Reverse AGCTTTTCCAAAAACGTACGCGGAATACTTCGATCTCTTGAATCGAAGTATTCCGCGTACGGG 
DHRS7c Forward GATCCCAGGTTGAGGAATACGATGTTTCAAGAGAACATCGTATTCCTCAACCTTTTTTGGAAA 









SFigure 1. Identification of DHRS7c in a combined gene array approach 
A. Venn diagram indicating the numbers of genes found to be differentially regulated in primary cultured 
cardio-myocytes treated with PE and Iso as compared to untreated cultures. Only those genes with a 
fold change of 2 or higher and a p value lower than 0.05 were included (N=3, each). B. Alignment of 
human (Hs), rat (Rn), chicken (Gg) and pufferfish (Tn) Dhrs7c. Underlined is the transmembrane 
segment and the conserved catalytic site is indicated in bold.* identical residue; : highly similar residue;  
























SFigure 2. myc-Dhrs7c expression in cardiomyocytes 
Cardiomyocytes were cultured in vitro and infected with recombinant adenovirus expressing myc-tagged 
Dhrs7c. After fixation and permeabilization myc-Dhrs7c was stained with anti-myc (green) anti-α-actininin 
staining (red) was used to specifically identify cardiomyocytes. The merged picture at the right also 






SFigure 3. Iso and PE concentration dependent downregulation of DHRS7c in neonatal rat cardiomyo-
cytes in vitro 
NRVCs were cultured for 24 hours in serum free medium and subsequently stimulated with Iso (A) or PE 
(B) at different concentrations. After 24 hours stimulation cells were harvested for analysis. DHRS7c 
expression in the different cultures was determined by RT-PCR and corrected for cyclophilin A 
expression (n=3). C. Same as above, but cells were now stimulated with 10 µM dobutamine. 









SFigure 4. Rescue of cell death phenotype of overexpressed Dhrs7c by concomitant siRNA silencing 
A. Light microscopy pictures of cells infected with myc-Dhrs7c expressing virus in the presence of 
siDhrs7c virus to silence Dhrs7c expression on in the presence of control siGL2 virus. Iso treatment is 
indicated. B. Western blot analysis of cell cultures treated with the different adenovirus combinations, 






SFigure 5. DHRS7c mRNA and protein expression is restricted to heart, muscle and skin 
Proteins were isolated from the indicated rat organs and tissues and used for Western blot analysis. 
Abbreviations: He=Heart, Br=Brain, Lu=Lung, Li=Liver, Ki=Kidney, In=Intestine, Mu=Muscle, 
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The short chain dehydrogenase/reductase (SDR) family member 7C (Dhrs7c) is 
predominantly expressed in heart and muscle. We recently showed that Dhrs7c is 
downregulated in rodent heart failure (HF) models and, importantly, also in cardiac biopsies 
from human HF patients. Moreover, this downregulation appeared to be linked to adrenergic 
stimulation and in vitro overexpression of Dhrs7 appeared to be lethal upon adrenergic 
activation. So far the exact function of this novel SDR has, however, remained elusive. In 
order to investigate the in vivo role of Dhrs7c in the heart, we generated transgenic mice with 
cardiac specific Dhrs7c overexpression. A transgenic (TG) mouse line with approximately 5 
fold overexpression was obtained. These mice behaved normal and did not show any 
obvious phenotype. Continuous adrenergic activation by infusion of isoproterenol and 
phenylephrine (Iso/PE) generated cardiac hypertrophy in these animals to a similar extend as 
compared to the not-transgenic (NTG) littermates. Also expression of the HF-marker ANP 
was similarly increased in both TG and NTG groups after Iso/PE infusion. Hemodynamic 
data was also not significantly different, although some trend was observed for a better 
fuction in (dPdtmin, dPdtmax, Tau g) in the TG group both at baseline and after Iso/PE 
infusion. Fibrotic scores were similar in TG and NTG groups, although we did observe a 
significantly increased expression of metalloproteinase II (MMP2) in the TG Iso/PE group as 
compared to the NTG Iso/PE group. This might suggest the presence of subtle differences in 
the extracellular matrix (ECM). Similarly Ca2+ handling might be somewhat altered in the TG 
Iso/PE treated group as compared to the NTG Iso/PE group, based on a significantly higher 
expression of the L-type Ca2+ channel. Thus although no major cardiac phenotype was 
observed, these small alterations might explain the slightly, albeit not significant, improved 












Heart failure (HF) is the common end-stage of many cardiovascular diseases. It is defined as 
the inability of the heart to supply adequate blood in response to systemic demands. The 
incidence of HF is 2-3% in developed countries, and rises sharply to 10% in those aged 75 
years and older 1. Despite therapeutic improvements in the past decades, HF is still 
associated with a high mortality and morbidity. It will be pivotal to improve our knowledge on 
this complex disease in order to identify new treatment opportunities.  
By whole genome gene expression analysis we recently identified a novel gene, 
termed Dhrs7c that showed heart failure associated gene expression 2. In particular, 
expression was downregulated in several animal HF models as well as in cardiac biopsies of 
human HF patients. In vitro studies with cultured primary neonatal rat cardiomyocytes 
revealed that Dhrs7c was strongly downregulated by isoproterenol (Iso, β-adrenergic agonist) 
and moderately downregulated by stimulation with phenyl-ephrine (PE, α-adrenergic agonist). 
Endothelin-1 (ET-1) stimulation of rat neonatal cardiomyocytes did not result in Dhrs7c 
downregulation, despite hypertrophy development similar to PE. This indicates that Dhrs7c 
downregulation is not linked to hypertrophy development, but rather associated with 
adrenergic stimulation. Also in vivo Dhrs7c downregulation was observed in mice after 
infusion with Iso/PE, which is in agreement with the in vitro results.  Interestingly, in vitro 
studies with Dhrs7c overexpression showed toxicity only in the presence of Iso, but not ET-1, 
suggesting that downregulation of Dhrs7c during adrenergic stimulation could be protective. 
Despite these observations the function of this predominantly heart and muscle expressed 
gene remained elusive.  
 To gain insights into the in vivo function of Dhrs7c in the heart, we constructed a 
transgenic mouse with cardiac-specific Dhrs7c overexpression. These transgenic mice 
showed increased Dhrs7c mRNA and protein expression in the heart only. Baseline cardiac 
parameters were determined as well as the effect of Iso/PE infusion on cardiac function.  
 
Methods and materials 
 
Transgenic animals  
The mouse DHRS7c gene (GeneBank: NM_001013013) was amplified by polymerase chain 
reaction (PCR) using primers containing a SalI and HindIII restriction site, respectively. 
Forward primer: GAAGTCGACACCATGGGGCTCATGGCTGTCCTG; Reverse primer: 







a previously described vector containing the cardiac specific α-MHC promoter 3. The BamHI 
fragment of this construct, containing α-MHC promoter and downstream Dhrs7c cDNA 
sequence, was subsequently used for pronuclear injections to generate Dhrs7c transgenic 
mice (FVB background). The transgenic mice were made by the UMCG mouse clinic (Marten 
Hofker) in collaboration with the Mayo Clinics. These transgenic mice were subsequently 
back crossed with C57BL/6 mice. In all experiments performed in this study, age- and sex-
matched non-transgenic littermates were used for comparison with the Dhrs7c transgenic 
mice.  
 
Groups and experimental protocols 
All animal protocols were approved by the Animal Ethical Committee of the University of 
Groningen. A total of 40 mice, 20 transgenic (TG) and 20 non-transgenic (NTG) littermates, 
were included in the present study. All mice were 12 to 14 weeks of age and 25 to 35 g of 
body weight. Both transgenic and non-transgenic mice were randomized to two groups, a 
saline group and an Iso/PE group. The Iso/PE group was treated with Iso (Sigma, 30mg/kg/d) 
and PE (Sigma, 30mg/kg/d) in saline with 0.1% ascorbic acid, whereas the saline group was 
treated only with saline and 0.1% ascorbic acid. All solutions were continuously infused for 7 
days via osmotic minipumps (CharlesRiver). The minipumps were implanted in the left flank 
of the mice under isoflurane (2% in air) anesthesia. After seven days, mice were 
anesthetized, and body weight (BW) was determined. Subsequently, hemodynamic 
measurements were made, animals were sacrificed, hearts were weighed and collected for 
histology and molecular analysis.  
 
Hemodynamic measurements 
All hemodynamic measurements were made via invasive catheterization. A pressure 
transducer catheter (Micro-Tip 1.4 French, Millar Instruments Inc., Houston, TX, USA) was 
inserted into the right common carotid artery and advanced into the aortic artery to measure 
the aortic blood pressure using a MPVS 400 processor at a sample rate of 1.000 Hz with 
Chart 5 (Millar Instruments Inc., Houston, TX, USA). The catheter was subsequently 
advanced into the left ventricle. After stabilization, maximal LV pressure, LV end-diastolic 
pressure, and heart rate were continuously recorded. The maximal rates of LV pressure 
increase and decrease (systolic dPdt and diastolic dPdt, respectively) were derived from a 
differential tracing of left intraventricular pressure. Analyses were performed offline using 
PVAN 3.6 software. 
 






For immunohistochemical analysis, hearts were fixed overnight with 10% neutral-buffered 
formalin at 4° C. After fixation, samples were subj ected to a dehydration series, embedded in 
paraffin and cut into 4 µM sections. Masson trichrome staining was performed to analyse 
collagen deposition. To quantify fibrosis, whole ventricle slice pictures were photographed 
using a Hamamatsu microscope, and fibrotic area was determined with Aperio's ImageScope 
software. Areas of fibrosis were calculated as percentage of total area of the left ventricle.   
 
Quantitative Real-Time PCR 
Quantitative Real-Time PCR (RT-PCR) was carried as described previously 4. All RT-PCR 
primer sequences are shown in supplemental Table 1. Results were normalized to the 
housekeeping gene GAPDH levels and are expressed in arbitrary units.  
 
Statistical analysis 
All data are expressed as mean±SEM. The differences between two groups were determined 
by a Student’s t test. Comparison between more than two groups data was assessed by 
One-Way ANOVA followed by post hoc Tukey test. A value of P<0.05 was considered to be 
statistically significant.  
 
 
Figure 1. Baseline characteristics of Dhrs7c-transgenic mice  
A, Western Blot of Dhrs7c in different tissues of TG and NTG animals. The overexpression of Dhrs7c in 
TG animals was limited to the heart. B, TG mice showed about 5 fold overexpression of Dhrs7c protein 
as compare with NTG littermates (*P<0.05, N=3). C, The ratio of heart weight (HW) to tibia length (TL) 
was similar in NTG and TG mice, (N=5). 










Baseline characterization of Dhrs7c transgenic mice 
To examine the role of Dhrs7c in vivo, transgenic mice were generated with cardiac specific 
Dhrs7c overexpression, using an α-MHC promoter driven construct. A total of 5 transgenic 
founders were generated, but only two founder lines showed increased expression in the 
heart. The line with highest cardiac expression was used in this study. As shown in Figure 1A, 
this transgenic mouse line showed about 5 fold increased Dhrs7c protein expression in the 
heart, as compared to non-transgenic littermates.  In other tissues, including skeletal muscle, 
skin and liver, no increased expression was observed, confirming that overexpression was 
confined to the heart (Figure 1B). We also analysed the heart weights of these animals, but 
did not observe differences between non-transgenic (NTG) and transgenic (TG) mice (Figure 
1C), also expression of ANP, a HF-marker 5, was normal (data not shown). No morphological 
abnormalities were observed in hearts from the TG mice.  
 
Iso/PE infusion and hypertrophy  
Since Iso/PE downregulates endogenous Dhrs7c both in vitro and in vivo 2 we decided to 
infuse Iso/PE in TG and NTG litermates using osmotic minipumps. The control groups 
obtained saline infusion. As shown in Figure 2A and 2B, Iso/PE infusion for 7 days resulted in 
substantial downregulation of endogenous DHRS7c mRNA levels in the NTG group, whereas 
in the TG group these levels slightly decreased, but albeit remained much higher as 
compared to the NTG group. Both in TG and NTG groups, Iso/PE resulted in marked cardiac 
hypertrophy, as determined by the increase in heart weight (HW) to tibia length (TL), but no 
differences were observed between these Iso/PE infused groups (Figure 2C). Also 
expression of the HF marker ANP was significantly increased in the Iso/PE treated TG and 
NTG groups (Figure 2D), suggesting that there are no major differences in HF development 
in both groups. 
 
Hemodynamic parameters 
After 7 days continuous infusion hemodynamic parameters in the Iso/PE and saline treated 
groups were determined by invasive catheterization. These hemodynamic parameters are 
presented in Table 1. Albeit not all significant, Iso/PE infusion resulted in a trend towards 
higher heart rate, mean arterial pressure (MAP) and end systolic pressure (ESP) in both NTG 
and TG groups. No major differences in these parameters were observed between the TG 
and NTG groups. The contractile parameters (dPdtmax, dPdtmin, Tau g) appeared to be 





slightly better in the TG group as compared to the NTG group, both after saline and Iso/PE 
infusion. Although none of them were significant, several p values almost reached 
significance (Tau g/HR p=0.059 and dPdtmax p=0.052 for TG versus NTG saline infusion 





Figure 2. Effects of Iso/PE infusion on Dhrs7c mRNA expression and cardiac hypertrophy  
A and B, Dhrs7c mRNA expression (corrected for GAPDH) was decreased in both NTG and TG mice 
after Iso/PE infusion, but only in NTG this downregulation was significant. Note the much higher 
expression levels in TG mice. C. Iso/PE infusion generated cardiac hypertrophy in both NTG and TG 
mice as shown by the ratio of heart weight to tibia length. D. ANP mRNA expression (corrected for 
GAPDH) was increased in both Iso/PE treated groups. N=9 for each group; *P<0.05 vs. NTG saline 
infusion, # P<0.05 vs. TG saline infusion. 
 
Table 1. Hemodynamic parameters after saline and Iso/PE infusion. 







HR (bpm) 538.8±24.9 624.8±20.6* 601.7±26.9 650.6±35.0 
MAP (mmHg) 83.4±3.3 89.8±2.9 78.6±2.8 96.1±4.6# 
ESP (mmHg) 106.3±2.6 110.4±2.9 104.4±4.4 114.6±3.4 
EDP (mmHg) 7.5±1.2 7.8±2.4 5.4±1.5 4.6±2.0 
dPdtmax/Pmax(LV) (s-1) 92.9±4.0 89.4±4.3 104.4±9.9 87.7±5.1 
dPdtmin/(ESP-EDP) (s-1) -100.4±5.9 -70.3±4.0* -107.0±7.2 -83.8±7.3” 
dPdtmax (mmHg/s) 9887.8±368.6 9991.0±408.3 11742.6±835.0^ 11040.2±1298.6 
dPdtmin (mmHg/s) -9878.7±536.6 -7181.1±359.2* -11250.5±780.0 -9967.5±1207.6% 
Tau g(ms)/HR(per sec) 1.09±0.10 1.43±0.16 0.8.±0.12$ 1.18±0.20 
All values are mean±SEM. 
* p<0.05 vs. NTG saline infusion; # p<0.05 vs. TG saline infusion; S p=0.059 vs. NTG saline infusion; 
 ^ P=0.052 vs. NTG saline infusion; % P=0.057 vs. NTG Iso/PE infusion. 







Fibrosis and histology 
Changes in the extracellular matrix (ECM) may affect cardiac function 6, 7 and we therefore 
performed Masson staining to quantify ECM deposition. Moreover a number of ECM markers 
were analysed by RT-PCR. As shown in Figure 3A and 3B, the ECM deposition was similarly 
increased in both NTG and TG Iso/PE treated groups. This corresponds with a similar 
increase in collagen I and III mRNA expression in the Iso/PE groups (Figure 3C, 3D). Also 
the expression of the ECM remodelling enzymes tissue inhibitor of metalloproteinases I 




Figure 3. Collagen deposition and expression in NTG ad TG mice after 7 days saline and Iso/PE 
infusion. 
A, Representative images of heart slices after Masson’s trichrome staining. The collagen rich area 
stained blue. B, Quantification of the percentage fibrotic area over the total left ventricular area. C and D 
shows increased mRNA expression of Collagen I and Collagen III after Iso/PE infusion in both NTG and 
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groups and a similar trend was visible for TIMP2 (Figure 4). Interestingly, the increase in 






Figure 4. mRNA expression of ECM remodelling enzymes.  
Expression was measured by RT-PCR and is relative to GAPDH. A, TIMP1. B, TIMP2. C, MMP2. N=9 








Figure 5. mRNA expression of  calcium channel encoding genes 
Expression was measured by RT-PCR and is relative to GAPDH. A, SERCA2. B, RYR2. C, LTCC.  and 
B, SERCA2 and RYR2 mRNA expression was higher in the TG Iso/PE group as compared to the NTG 
Iso/PE group,  though not statistically significant (P=0.007 and 0.079 respectively). $ P<0.05 vs. NTG 
Iso/PE infusion. 
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Calcium related gene expression  
Dhrs7c is a sarcoplasmatic reticulum (SR) localized protein 2. Since the SR plays an 
important role in controlling cellular calcium levels 8, we also investigated the mRNA 
expression of several calcium related SR proteins. In particular we determined the 
expression of the Ca2+ channelsryanodine receptor 2 (RYR2) 9, sarcoplasmic reticulum Ca2+-
ATPase (SERCA2) 10. In addition the expression of the T-tubule localized L-type Ca2+ 
channel (LTCC) 11 was investigated. SERCA2 was downregulated in the NTG group treated 
with Iso/PE, whereas SERCA2 remained almost constant in the TG group. RYR2 expression 
appeared to be somewhat elevated in the TG groups as compared to the NTG groups and 
the same was true for LTCC (Figure 5). The latter showed even a significant difference 




Dhrs7c is a short chain dehydrogenase reductase, which is prominantly expressed in heart 
and is downregulated upon HF development and/or adrenergic stimulation. In the present 
study we investigated the effect of cardiac specific overexpression of Dhrs7c in transgenic 
mice. Despite a 5 fold overexpression of Dhrs7c protein, no spontaneous cardiac phenotype 
was observed. Also upon Iso/PE infusion, a condition that downregulates endogenous 
Dhrs7c expression and induces HF development, no major differences were observed. Only 
a slight trend towards improved function was observed in the TG groups and some small 
differences in expression of genes associated with fibrosis and Ca2+ handling could be 
observed.  
To our knowledge this is the first study describing a transgenic mouse line with 
cardiac specific overexpression of Dhrs7c. Using this mouse line we aimed to dissect a 
potential cardiac phenotype associated with cardiac specific Dhrs7c overexpression. No 
spontaneous phenotype was observed in these transgenic mice and heart weights, 
expression of HF markers were all indistinguishable from the NTG group. This is in line with 
our previous in vitro studies using neonatal cardiomyocytes in which no obvious spontaneous 
phenotype was observed upon overexpression.  
Previously we showed that in HF patients, in HF animal models and upon 
adrenergic stimulation Dhrs7c expression is profoundly downregulated. Moreover, 
overexpression of Dhrs7c in neonatal cardiomyocytes in vitro resulted only in cell death in the 
presence of adrenergic stimulation. We therefore decided to investigate cardiac function in 
Dhrs7c-TG mice after 7 days Iso/PE infusion. Surprisingly, no major phenotype was 





observed. Only in parameters for contractility some differences, albeit just not significant, 
were observed between NTG and TG groups. In particular the relaxation constant (dPdtmin) 
and the contraction constant (dPdtmax) appeared to be improved in the TG group as 
compared to the NTG group and also a trend towards improved Tau g was observed in the 
TG group. This could be related to changes in the ECM 6, 7, but no obvious differences were 
observed in collagen expression or in fibrotic scores. Only, MMP2 expression was 
significantly elevated in Dhrs7c-TG mice treated with Iso/PE as compared to the NTG group. 
Whether this indicates that there might be more subtle changes in ECM function requires 
more detailed investigation of the ECM matrix. MMP2 has previously been shown to be a 
cAMP responsive gene 12 and hence the elevated upregulation of MMP2 may be caused by 
a hyper β-adrenergic response in the TG cardiomyocytes. It might therefore be interesting to 
investigate the expression of other cAMP responsive MMPs such as MT1-MMP and MMP13. 
The observed small differences in cardiac function could also be mediated by 
altered calcium handling 13. We therefore determined RYR2 9, SERCA2 10 and LTCC 11 
mRNA expression. All the three genes were higher in TG than in NTG mice after Iso/PE 
infusion, though only LTCC was statistically significant. Whether this explains the observed 
small changes in contractility would require further research, but all these genes have been 
shown to be associated with alterations in Ca2+ handling and are linked to different cardiac 
diseases, such as cardiac myopathy, arrhythmias and heart failure 9, 11, 14, 15.  
The lack of major cardiac differences in the Dhrs7c TG mice could have multiple 
reasons. First, Dhrs7c might only play a subtle role in the heart or functions into pathways 
that we did not investigate. The strong conservation of this gene in all vertebrates does, 
however, indicate an important function. The absence of a clear phenotype might therefore 
also be related to the limited overexpression (5 fold), which may not be sufficient to elicit a 
phenotype. In vitro, a much stronger phenotype was observed which could be due to the 
much stronger overexpression (>20 fold), but may also be related to the use of neonatal rat 
cardiomyocytes that express lower endogenous levels as compared to adult cardiomyocytes 
and might be more susceptible to Dhrs7c overexpression. We did not check the expression 
of other Dhrs7c family members (like Dhrs7 and Dhrs7b) and we cannot exclude that 
repression of these genes might compensate for Dhrs7c overexpression in the TG animals. 
Finally, we only analysed it in relatively young animals and it may be rewarding to evaluate 
whether overexpression of Dhrs7c would generate a stronger phenotype in aged animals.   
In conclusion, we successfully generated a transgenic mouse with cardiac-specific 
Dhrs7c overexpression. The present study provides a basic characterization of this TG 
mouse line. The Dhrs7c-TG mice showed no spontaneous cardiac phenotype at baseline, or 







show significant changes. Further investigations will be required to reveal the function of 




We like to thank Bart van der Sluis for his help in generating the Dhrs7c transgenic mice. We 
like to thank Bianca Meijeringh for expert biotechnical assistance and Martin Dokter for 




1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van 
Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, ESC Committee for 
Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The 
task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. 
developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the european society of 
intensive care medicine (ESICM). Eur J Heart Fail. 2008;10:933-989.  
2. Lu B, Tigchelaar W, Ruifrok WP, van Gilst WH, de Boer RA, Sillje HHW. DHRS7c, a novel cardiomyocyte expressed 
gene that is downregulated by adrenergic stimulation and in heart failure. Eur J Heart Fail. In press.  
3. Gulick J, Subramaniam A, Neumann J, Robbins J. Isolation and characterization of the mouse cardiac myosin heavy 
chain genes. J Biol Chem. 1991;266:9180-9185.  
4. Lu B, Mahmud H, Maass AH, Yu B, van Gilst WH, de Boer RA, Sillje HH. The Plk1 inhibitor BI 2536 temporarily 
arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro. PLoS One. 2010;5:e12963.  
5. Yasue H, Obata K, Okumura K, Kurose M, Ogawa H, Matsuyama K, Jougasaki M, Saito Y, Nakao K, Imura H. 
Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathy. J Clin 
Invest. 1989;83:46-51.  
6. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: Function, structural remodeling and 
regulatory mechanisms. J Mol Cell Cardiol. 1994;26:279-292.  
7. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of 
myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 
2002;105:2512-2517.  
8. Priori SG, Chen SR. Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res. 
2011;108:871-883.  
9. Meissner G. Molecular regulation of cardiac ryanodine receptor ion channel. Cell Calcium. 2004;35:621-628.  
10. Kawase Y, Hajjar RJ. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: A potent target for 
cardiovascular diseases. Nat Clin Pract Cardiovasc Med. 2008;5:554-565.  





11. Satin J, Schroder EA, Crump SM. L-type calcium channel auto-regulation of transcription. Cell Calcium. 
2011;49:306-313.  
12. Guo D, Kassiri Z, Basu R, Chow FL, Kandalam V, Damilano F, Liang W, Izumo S, Hirsch E, Penninger JM, Backx 
PH, Oudit GY. Loss of PI3Kgamma enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin 
adhesion complexes and extracellular matrix in response to early biomechanical stress. Circ Res. 2010;107:1275-1289.  
13. Lompre AM, Hajjar RJ, Harding SE, Kranias EG, Lohse MJ, Marks AR. Ca2+ cycling and new therapeutic 
approaches for heart failure. Circulation. 2010;121:822-830.  
14. Zhou Q, Xiao J, Jiang D, Wang R, Vembaiyan K, Wang A, Smith CD, Xie C, Chen W, Zhang J, Tian X, Jones PP, 
Zhong X, Guo A, Chen H, Zhang L, Zhu W, Yang D, Li X, Chen J, Gillis AM, Duff HJ, Cheng H, Feldman AM, Song LS, 
Fill M, Back TG, Chen SR. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ 
release. Nat Med. 2011;17:1003-1009.  
15. Stolen TO, Hoydal MA, Kemi OJ, Catalucci D, Ceci M, Aasum E, Larsen T, Rolim N, Condorelli G, Smith GL, Wisloff 
U. Interval training normalizes cardiomyocyte function, diastolic Ca2+ control, and SR Ca2+ release synchronicity in a 



































Table S1. Sequences of oligonucleotide primers used for quantitative real-time PCR 
Genes 5’-3’ Forward 5’-3’ Reverse 
DHRS7c GGAGAACAGGCCAGATTGTG CTCGGAGGCAGTCAAAGAAG 
ANP ATGGGCTCCTTCTCCATCAC TCTACCGGCATCTTCTCCTC 
GAPDH CATCAAGAAGGTGGTGAAGC ACCACCCTGTTGCTGTAG 
Collagen 1a1 CTTCACCTACAGCACCCTTGTG CTTGGTGGTTTTGTATTCGATGAC 
Collagen III TCGGAACTGCAGAGACCTAAA CCCCAGTTTCCATGTTACAGA 
α-MHC GACAACTCCTCCCGCTTTGG AAGATCACCCGGGACTTCTC 
β-MHC CGAGGCAAGCTCACATATAC GTCACAATCATGCCGTGCTG 
TIMP1 CTGCTCAGCAAAGAGCTTTC CTCCAGTTTGCAAGGGATAG 
TIMP2 GGTACCAGATGGGCTGTGAGTG CTGTGACCCAGTCCATCCAGAG 
MMP2 CCCTGATGTCCAGCAAGTAG GGAGTCTGCGATGAGCTTAG 
SERCA2 CTGCTGGCAGCATGTATATC ACAAACGGCTCTACAAAGGC 
RYR2 TTGGCAGCAGAAGGATTTGG GCACAAAGGTGCAGATAGAC 
LTCC AGATCCAGCCATCTCCAAAGAG CCTTTTGTCGCTTTAGACATTCC 
 
ANP, atrial natriuretic peptide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; α/β-MHC, α/β-
myosin heavy chain; TIMP1/2, tissue inhibitor of metalloproteinases 1/2; MMP2, matrix metalloproteinase 



















Summary, general discussion 








Heart failure (HF) is a complex and progressive disorder and is defined as a condition in 
which the heart cannot supply sufficient blood and oxygen to keep up the body’s demands. 
Several pathological processes are involved in the onset and progression of HF including 
cardiac remodeling 1 and re-entering of the fetal gene program 2. The latter is a hallmark of 
HF development, but the role of this altered gene program in HF is still poorly understood. 
Some gene expression changes appear to be beneficial, whereas others, like SERCA2 3, 4, 
are clearly detrimental, as described in Chapter 2. The aim of this thesis was to generate an 
inventory of hypertrophy associated gene expression changes. This would provide a more 
elaborate view of all the gene expression changes and could reveal new hypertrophy related 
genes that were hitherto not linked to this disease. These novel genes could be subject to 
further investigation and in this thesis we also described the further investigation of one of the 
identified genes, termed Dhrs7c.  
 
In Chapter 2, we extensively reviewed two major components of cardiac remodeling, 
hypertrophy and fibrosis. In addition gene expression changes associated with these 
processes were described. In order to generate a more elaborate list of genes differentially 
expressed in HF and hypertrophy, it was decided to investigate expression changes in 
multiple models. The latter could provide a more robust list of genes with HF/hypertrophy 
associated expression, and exclude model specific alterations. Two in vivo rat models of HF 
were chosen as well as an in vitro model of cultured primary neonatal rat cardiomyocytes. 
The latter would also allow detection of gene expression changes specific to cardiomyocytes.  
 
In Chapter 3, we describe the set-up of the in vitro primary rat cardiomyocyte culturing 
system and the induction of hypertrophy by neurohormonal factors. Since fibroblast 
contamination is a general problem in primary cardiomyocyte cultures we also investigated 
whether a novel anti-proliferative drug, BI 2536, targeting polo-like kinase 1 (Plk1) 5, could 
prevent fibroblast overgrowth in these cultures. We could show that BI 2536 had a profound 
effect on cardiac fibroblast proliferation in vitro and arrested these cells in mitosis with an 
IC50 of about 43 nM. Further analysis revealed that prolonged mitotic arrest resulted in cell 
death for about 40% of cardiac fibroblasts. The remaining cells showed an interphase 
morphology with mostly multi and micro nuclei. This indicates that a significant number of 
primary fibroblasts were able to escape BI 2536 induced mitotic arrest and apparently 
became aneuploid. No effects were observed on cardiomyocytes and hypertrophic response 
upon endothelin-1 and phenylephrine stimulation was normal in the presence of BI 2536. 
This indicates that BI 2536 had no adverse effects on terminally differentiated cells and still 





allowed proliferation independent growth induction in these cells. Thus, although BI 2536 
could reduce fibroblast numbers, without apparent adverse effects to cardiomyocytes, it 
could not fully eliminate these cells from the cardiomyocyte cultures. Short culturing times to 
prevent overgrowth remain therefore a prerequisite in cardiomyocyte culturing.  
 
Having established an in vitro cardiomyocyte culturing system to investigate hypertrophy, we 
subsequently started the investigation of differential gene expression in response to 
hypertrophic stimuli (Chapter 4). For this, cells were stimulated with isoproterenol (Iso, a β-
adrenergic agonist), phenylephrine (PE, an α-adrenergic agonist) or endothelin-1 (ET-1). All 
these agents generated hypertrophy and induction of the fetal gene program, as determined 
by ANP expression. Subsequently, gene array analysis was performed for each culture 
condition. In parallel, gene expression was analysed in two different in vivo rat HF models, 
namely post-MI HF and Ren 2 rats that overexpress mouse renin thereby generating 
hypertension which results in HF development. Gene expression changes as compared to 
the respective controls (non-treated cardiomyocytes or non-HF rats) were determined and 
the obtained lists with differential expressions were compared with each other. This 
generated a concise list of 62 genes differentially expressed in hypertrophy/HF. Additional 
gene ontology analysis revealed clear differences between in vitro and in vivo models. The 
extracellular matrix, wounding and stress specific genes were enriched in the in vivo list; 
most of them are predominantly expressed by non-cardiomyocytes in heart tissue which 
explains the absence in the in vitro cardiomyocyte experiments. The terpenoid and steroid 
biosynthesis pathways on the other hand were upregulated in the in vitro models. Importantly, 
we identified the common known HF markers like ANP, BNP, TIMP1, FHL1 and LGALS3 
validating this method 6-8. Moreover, the presence of genes not previously associated to 
hypertrophy/HF suggests that this combined in vitro/in vivo approach is a powerful method to 
identify new genes potentially associated with HF. Amongst these are PTGIS, AKIP1 and 
Dhrs7c, which could be interesting targets for further investigations. The presence of 
TNFRSF12a in our list, which was identified as a HF indicator by others 9 during the course of 
our experiments, further confirmed that potential new HF associated genes could be 
identified by this method. Taken together, this study provided insight in the differences 
between the in vivo and in vitro models; and at the same time, it provided a robust set of 
hypertrophy/HF associated genes.   
 
From the set of genes identified in Chapter 4, a short chain dehydrogenase/reductase, 







cardiomyocytes. In Chapter 5, we confirmed that DHRS7c was downregulated in our 
different animal HF models, not only at mRNA level, but also at protein level. Moreover, like 
in vitro, the expression of Dhrs7c could be downregulated in vivo by an Iso/PE infusion, 
suggesting that adrenergic stimulation could be an important mediator of this downregulation. 
The absence of ET-1 mediated downregulation in vitro, despite hypertrophy formation, did 
indicate that downregulation was not directly linked to hypertrophy, but instead might be 
correlated to adrenergic stimulation. Importantly, we could extend our investigations to 
human cardiac biopsies from HF patients and show that Dhrs7c is also downregulated in 
human HF patients. Therefore this could also have clinical relevance. Interestingly, Dhrs7c 
expression is confined to muscle, heart and skin indicating that it has a tissue specific 
function. Within the heart, expression was only observed within cardiomyocytes and was 
absent in the non-cardiomyocyte cell population. Dhrs7c appeared to localize to the 
endo/sarcoplasmatic reticulum in these cells, but so far we could not reveal its function in this 
organelle. Overexpression and silencing of Dhrs7c did not provide an obvious phenotype in 
vitro, except in the presence of adrenergic stimulation. Under these conditions, cell rapidly 
died, but the molecular mechanism behind this cell death remained unclear and did not 
appear to be apoptosis related. It did, however, suggest that downregulation could be 
important under conditions of adrenergic stimulation. 
 
To further investigate the functional effects of Dhrs7c overexpression, a transgenic mouse 
with cardiac specific overexpression of Dhrs7c was generated, as described in Chapter 6. 
Out of 5 mouse lines only one transgenic (TG) mouse line showed substantial Dhrs7c 
overexpression of approximately 5 fold at the protein level. These TG mice behaved normally 
and did not show any obvious phenotype. The HF markers (e.g. ANP), fibrotic and 
hemodynamic parameters were also similar in TG and non-transgenic littermate (NTG) group 
after continuous adrenergic activation via Iso/PE infusion. Only some differences were 
observed in the expression of metalloproteinase II (MMP2) and L-type calcium channel 
(LTCC) in the TG Iso/PE group as compared to the NTG Iso/PE group. These differences are, 
however, minor and it is not clear if these differences are relevant. The lack of a spontaneous 
and Iso/PE induced phenotype might have numerous reasons as discussed in Chapter 6. 
One of them is the limited overexpression of only 5 fold, which might not be sufficient to elicit 
a phenotype. The strong conservation of this gene in vertebrates and its tissue specific 
expression clearly suggest an important evolutionary conserved function of this protein. 
Elucidation of its function would require biochemical analysis of this protein, including the 
identification of its potential substrates. We did try to purify sufficient recombinant protein to 





perform such analysis, but were unfortunately not able to obtain it in a functional soluble form. 
In addition to biochemical analysis, the generation of a Dhrs7c knock-out mouse may shed a 
better light on the function of this intriguing protein.   
 
Overall, in this thesis we (1) provided a method to inhibit fibroblast proliferation in 
cardiomyocyte culturing; (2) compared the gene expression between in vivo and in vitro 
models; (3) further investigated Dhrs7c, one of the novel HF associated genes from our gene 
list. Future studies on Dhrs7c would probably require the generation of a knock-out mouse to 
reveal its function. The generated gene list also contained a number of other interesting 
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Hartfalen is een complexe en progressieve aandoening waarbij het hart niet genoeg bloed en 
zuurstof kan rondpompen om aan de behoefte van het lichaam te voldoen. Verschillende 
pathologische processen zijn betrokken bij het ontstaan en het verdere verloop van hartfalen, 
waaronder hart remodeling 1. Dit omvat onder anderen hypertrofie (groei) van de 
cardiomyocyten (hartspiercellen), fibrose, en de reactivatie van foetale genexpressie 2. Deze 
veranderde genexpressie is een belangrijk kenmerk van hartfalen, maar de rol hiervan is nog 
niet duidelijk. Terwijl sommige veranderingen in de genexpressie een gunstig effect lijken te 
hebben, hebben andere, zoals SERCA2 3, 4, een duidelijk negatief effect, zoals beschreven in 
hoofdstuk 2. Het doel van het in dit proefschrift beschreven onderzoek, was het maken van 
een overzicht van alle genexpressie veranderingen die optreden tijdens hypertrofie en 
hartfalen ontwikkeling. Een dergelijk overzicht zou een beter inzicht kunnen geven in 
hartfalen en zou kunnen leiden tot de identificatie van genen die nog niet eerder met  
hartfalen in verband zijn gebracht. Deze nieuwe genen kunnen vervolgens nader onderzocht 
worden, zoals dit in dit proefschrift is gedaan voor één van de nieuw geïdentificeerde genen, 
genaamd Dhrs7c. 
 
In hoofdstuk 2 worden de twee belangrijkste componenten van hart remodeling beschreven, 
namelijk hypertrofie en fibrose. Ook de bekende genexpressie veranderingen van de genen 
die betrokken zijn bij deze processen worden hier beschreven. Om een uitgebreide lijst te 
verkrijgen van alle genen, die differentieel tot expressie komen in zowel hartfalen als 
hypertrofie hebben we vervolgens besloten de genexpressie veranderingen in diverse 
modellen van hartfalen/hypertrofie te bestuderen. Dit zou een betrouwbare lijst kunnen 
opleveren met genen waarvan de expressie geassocieerd is met hartfalen/hypertrofie en ook  
model specifieke veranderingen aan het licht kunnen brengen. Er werden hiervoor twee in 
vivo rat modellen van hartfalen gebruikt, gecombineerd met een in vitro model bestaande uit 
een cel kweek van primaire neonatale rat cardiomyocyten. Door het gebruik van dit in vitro 
model kon ook de cardiomyocyt specifieke genexpressie bestudeerd worden. 
 
In hoofdstuk 3 hebben we de opzet beschreven van het in vitro kweek systeem van primaire 
neonatale rat cardiomyocyten en de inductie van hypertrofie door neurohumorale factoren 
hierin. De contaminatie van primaire cardiomocyten met fibroblasten is in deze kweek een 
algemeen bekend probleem. Daarom hebben we eerst onderzocht of een nieuw anti-
proliferatieve stof, BI 2536, dat als target polo-like kinase 1 (Plk1) 5 heeft, de vermeerdering  
van fibroblasten kon voorkomen. We hebben laten zien dat BI 2536 een remmend effect had 






mitose met een IC50 van ongeveer 43 nM. Verdere analyse liet zien dat gedurende een 
langere stagnatie van de celcyclus ongeveer 40% van de cardiale fibroblasten dood gingen. 
De overblijvende cellen hadden de morfologie van interfase cellen met meestal meerdere 
kernen en microkernen. Dit wijst erop dat een significant aantal primaire fibroblasten konden 
ontkomen aan de door BI 2536 geïnduceerde stagnatie in de mitotische fase, en blijkbaar 
aneuploïd werden. Er werden geen effecten gezien op de cardiomyocyten en de hypertrofe 
respons gedurende stimulatie met endotheline-1 en phenylephrine was normaal na de 
behandeling met BI 2536. Dit duid erop dat BI 2536 geen bijwerkingen had op terminaal 
gedifferentieerde cellen en dat proliferatie onafhankelijke groei-inductie nog steeds mogelijk 
was. Kortom, hoewel BI 2536 het aantal fibroblasten kon verminderen zonder bijwerkingen 
op cardiomyocyten te hebben, kon BI 2536 niet alle fibroblasten uit de cardiomyocyten 
kweek elimineren.  
 
Nadat we de methode voor de in vitro cardiomyocyten kweek hadden opgezet om hypertrofie 
te onderzoeken, hebben we de verschillen in genexpressie in reactie op hypertrofe stimuli 
onderzocht (hoofdstuk 4). Hiervoor werden de cellen gestimuleerd met isoproterenol (Iso, 
een β-adrenerge antagonist), phenylephrine (PE, een α-adrenerge agonist) of endotheline-1 
(ET-1). Al deze stoffen veroorzaakten hypertrofie en de reactivatie van de expressie van de 
foetale genen, welke we hebben bepaald door de ANP expressie te meten. Vervolgens 
hebben we een gene array analyse gedaan op elke kweek conditie en op twee verschillende 
in vivo modellen van hartfalen bij de rat, namelijk post-myocard infarct (post-MI) en in Ren 2 
ratten. Laatstgenoemde ratten brengen het muizen renine gen tot overexpressie waardoor de 
dieren een hoge bloeddruk krijgen dat uiteindelijk leidt tot de ontwikkeling van hartfalen. De 
veranderingen in de genexpressie ten opzichte van de bijbehorende controles (niet 
behandelde cardiomyocyten of ratten zonder hartfalen) werden bepaald en de verschillen in 
de expressies werden met elkaar vergeleken. Dit resulteerde in een beknopte lijst met 62 
genen die verschillend tot expressie kwamen in de hypertrofie/hartfalen modellen. Gene 
ontology analyse liet tevens duidelijke verschillen zien tussen de  in vitro en in vivo modellen. 
Extracellulaire matrix genen en genen die geactiveerd worden bij verwonding en stress 
waren veel voorkomend in de lijst met de in vivo modellen; de meesten komen voornamelijk 
tot expressie in de niet-cardiomyocyt cellen in het hart wat tevens de afwezigheid verklaarde 
in de in vitro cardiomyocyten experimenten. Daar tegenover staat dat de terpenoïde en 
steroïde biosynthese reacties verhoogd waren in de in vitro modellen. Als positieve 
bevestiging van de analyse hebben we de algemeen bekende markers voor hartfalen 
gevonden zoals ANP, BNP, TIMP1, FHL1 en LGALS3 6-8. Dat we naast deze bekende genen 
 





ook genen vonden die niet eerder geassocieerd werden met hypertrofie/hartfalen maakt 
duidelijk dat deze combinatie van in vitro/in vivo modellen een goede benadering is om 
nieuwe genen te identificeren, die mogelijk betrokken zijn bij hartfalen. Enkele van deze 
nieuwe genen zijn PTGIS, AKIP1 en Dhrs7c welke  interessant zijn voor verder onderzoek. 
De aanwezigheid van TNFRSF12a in onze lijst, welke tijdens onze studie ook door anderen 
werd geïdentificeerd als een hartfalengeassocieerd 9 gen bevestigde dat nieuwe hartfalen 
genen geïdentificeerd konden worden met deze methode. Kortom, deze studie gaf inzichten 
in de verschillen tussen in vivo en in vitro modellen en leverde tegelijkertijd een beknopte lijst 
van hypertrofie/hartfalen geassocieerde genen op. 
 
Van de geïdentificeerde genen die werden beschreven in hoofdstuk 4, liet een short chain 
dehydrogenase/reductase, DHRS7c, een consistente verlaging in de expressie zien in al 
onze modellen met uitzondering van ET-1 behandelde cardiomyocyten. In hoofdstuk 5 
hebben we bevestigd dat de expressie van DHRS7c naar beneden ging in onze 
verschillende diermodellen van hartfalen, niet alleen op mRNA niveau maar ook op eiwit 
niveau. Net als in de in vitro modellen was de expressie van Dhrs7c verlaagd na iso/PE 
infusie in vivo. Dit suggereerde dat adrenerge stimulatie belangrijk zou kunnen zijn voor deze 
verlaging in de genexpressie. Dat ET-1 geen verlaging van de genexpressie in vitro 
veroorzaakte, ondanks de hypertrofie ontwikkeling, laat zien dat verminderde expressie van 
Dhrs7c niet direct gecorreleerd is met hypertrofie maar waarschijnlijk gerelateerd is aan 
adrenerge stimulatie. Daarnaast konden we ook laten zien dat de expressie van Dhrs7c 
verminderd was in patiënten met hartfalen door humane cardiale biopten te analyseren. Dit 
effect kan dus mogelijk klinische relevantie hebben. Dhrs7c wordt alleen in de spier, het hart 
en de huid tot expressie gebracht, wat kan duiden op een weefsel specifieke functie. In het 
hart werd de expressie alleen waargenomen in de cardiomyocyten en niet in de niet-
cardiomyocyt cellen. In deze cellen leek Dhrs7c gelokaliseerd te zijn in het 
endo/sarcoplasmatische reticulum, maar tot nog toe hebben we niet de functie in dit organel 
kunnen ontrafelen. We hebben ook geen duidelijk fenotype waargenomen in cellen waarin de 
expressie van Dhrs7c in vitro verhoogd (overexpressie) of verlaagd (silencing) werd, behalve 
in de aanwezigheid van adrenerge stimulatie. Onder deze condities gingen de cellen snel 
dood, maar de moleculaire mechanismen achter deze celdood bleven onduidelijk. Het leek 
echter niet apoptose gerelateerd te zijn. Deze waarneming duidde er op dat verminderde 







Om de functionele effecten van de overexpressie van Dhrs7c te onderzoeken hebben we 
een transgene (TG) muis gemaakt met hart specifieke overexpressie van Dhrs7c. Dit hebben 
we beschreven in hoofdstuk 6. Van de vijf verschillende foklijnen gaf slechts één TG 
muislijn een substantiële vijfvoudige Dhrs7c verhoging op eiwit niveau. Deze dieren lieten 
geen afwijkend gedrag zijn en hadden geen spontaan fenotype. De hartfalen markers 
(bijvoorbeeld ANP), maar ook de fibrotische en hemodynamische parameters waren gelijk in 
de TG en niet transgene dieren (NTG), ook na een continue adrenerge activatie via iso/PE 
infusie.  Alleen in de expressie van metalloproteinase II (MMP2) en L-type Calcium channel 
(LTCC) werden enkele verschillen waargenomen tussen de TG Iso/PE groep en de NTG 
Iso/PE groep. Deze verschillen waren echter klein en het is nog niet duidelijk of deze 
verschillen relevant zijn. Het ontbreken van een spontaan en Iso/PE geïnduceerd fenotype 
kan meerdere redenen hebben die besproken worden in hoofdstuk 6. Een van deze 
redenen is de beperkte overexpressie van slechts 5-voud, wat misschien niet genoeg is om 
een fenotype te induceren. De sterke conservatie van dit gen in gewervelden en de tissue 
specifieke expressie suggereren echter duidelijk een belangrijke evolutionair geconserveerde 
functie van dit eiwit. Om de functie te verhelderen zijn biochemische analyses van dit eiwit 
nodig, waaronder de identificatie van de potentiële substraten. We hebben geprobeerd om 
genoeg recombinant eiwit te maken om deze analyses te doen, maar we hebben helaas dit 
eiwit niet in oplosbare vorm kunnen zuiveren. Naast de biochemische analyses zou de 
Dhrs7c knock-out muis ook kunnen helpen de functie van dit fascinerende eiwit op te 
helderen. 
 
Kortom, in dit poefschrift hebben we (1) een methode beschreven om de proliferatie van 
fibroblasten te remmen in de kweek van cardiomyocyten; (2) de genexpressies vergeleken 
tussen in vivo en in vitro modellen van hartfalen; (3) de expressie en mogelijke functie van 
Dhrs7c, een nieuw ontdekt gen dat niet eerder met hartfalen was geassocieerd, onderzocht.  
In toekomstig onderzoek, zal waarschijnlijk een zogenaamde knock-out muis moeten worden 
gemaakt, waarmee de functie van Dhrs7c opgehelderd kan worden. De verkregen lijst met 
genen omvatte ook een aantal andere interessante kandidaten en verder onderzoek van 




1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. experimental observations and clinical 
implications. Circulation. 1990;81:1161-1172.  
 





2. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: A 
strong hypothesis. Heart Fail Rev. 2007;12:331-343.  
3. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just H, 
Hasenfuss G. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 
1995;92:778-784.  
4. Schwinger RH, Bohm M, Schmidt U, Karczewski P, Bavendiek U, Flesch M, Krause EG, Erdmann E. Unchanged 
protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and ca(2+)-ATPase activity of cardiac 
sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation. 
1995;92:3220-3228.  
5. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol. 
2004;5:429-440.  
6. Zhang QJ, Chen HZ, Wang L, Liu DP, Hill JA, Liu ZP. The histone trimethyllysine demethylase JMJD2A promotes 
cardiac hypertrophy in response to hypertrophic stimuli in mice. J Clin Invest. 2011;121:2447-2456.  
7. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 
2010;7:1-8.  
8. Kramer F, Milting H. Novel biomarkers in human terminal heart failure and under mechanical circulatory support. 
Biomarkers. 2011;16 Suppl 1:S31-41.  
9. Chorianopoulos E, Heger T, Lutz M, Frank D, Bea F, Katus HA, Frey N. FGF-inducible 14-kDa protein (Fn14) is 
regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by 






















































































Time flies by. It seems just yesterday that I arrived in this mysterious country and started a 
totally new, but interesting life. I still remember four and a half years ago, in the chilly 
midnight of 16 August 2007 when Cheng waited for me on the platform at the railway station 
of Groningen. Later at dawn of the next day, Dr. Qu Ning, whom I had never met before, 
drove me to Cheng and Lili’s. If I was a fatalist, I would have known the PhD life here would 
not be easy, but with the help of many warm-hearted people, this task would not be 
unachievable either. And now, in the last part of my thesis, I would like to thank all the people 
who have walked along beside me and have helped me during these years. 
 
First of all, I want to express my gratitude to my promoter, Prof. dr. Wiek H. van Gilst. Dear 
Wiek, thank you for your support in my scientific research during these four years. You 
always have a broad view of the design of the experiments and the translation of the results. 
You let me understand that in research, as in life, it is important to face the reality and to 
focus on the important things. And I have no doubt that the group of Experimental Cardiology 
will become larger and stronger in the future.  
 
Secondly, my utmost thanks go to my daily supervisor, Dr. Herman H. W. Silljé. Dear 
Herman, your passion in research and your enthusiasm in learning have had a great impact 
on me. Without your help in my studies, I cannot imagine I would have ever made it this far 
with my PhD in the Netherlands. Without your correction of the manuscripts, I would have 
never finished this thesis. I will always appreciate your patient guidance in my research work. 
And I will always remember you being there any time when there is problem to be solved. I 
hope someday I have the ability and opportunity to return your kindness and support when I 
am well-established in China. Again, thank you! 
I would also like to thank my other co-promoter, Dr. Rudolf A. de Boer. Dear Rudolf, I am 
impressed by your efficiency and optimism on research work. You always find the brighter 
side even in a disappointing situation. I valued the great combination of yours and Herman’s 
opinion which really speeded up my project. I have learned a lot from you, especially since I 
am going back to China to be a clinical doctor, and also continue my research interests.  
 
My word of thank goes also to the members of my reading committee, Prof. dr. M.P. van den 
Berg, Prof. dr. A.A. Voors and Prof. dr. J.H. Kingma, for critically evaluating my thesis.  
 
A special thanks to Riekje Banus, Mathilde Pekelaar and Maaike H. Bansema from GUIDE, 






I owe my sincere thanks to the people from Experimental Cardiology. Thanks to all PhD 
students and post docs: Reinout, Irma, Hisko, Liza, Anne-Margreet, Mariusz, Willem-Peter, 
Daan, Megan, Niek, Vincent, Atze, Leonie, Jardy, Lennaert, Michael, Frank, Nicolas, Hasan, 
Irene, and Maxi, for all the wonderful presentations and good ideas you gave at every Lunch 
and PhD meeting. I hope we can work together again in the future. Dear Reinout, I could 
always turn to you for help when I had a problem with the Millar data. Dear Irma, thank you 
for the detailed information on preparing for thesis printing and promotion. Dear Megan, it is 
so nice to have a native-English speaker next to me and help me with the grammar.  
I would like to thank Carla, Danielle and Marjan. Thank you for your help. 
I am also grateful for the technical support of Martin, Linda, Silke, Bibiche, Inge, Janny, Annet 
and Germaine. Dear Martin, thank you for your efficient work in immunochemistry staining. 
Dear Silke, you are always willing to help people. It is very nice to have you in the group. The 
people from CDL, Bianca, Annemiek, Andre and Michel, thank you for helping me with the 
animal experiment. Thanks to Klaas from the Imaging Center. 
I would like to thank Maggie, Peter, Adriaan and Marry at Clinical Pharmacology. Dear 
Adriaan, thank you for sending me to central station before I leave for China. You were the 
guide for my badminton skills. I hope someday I can be your tour guide in Harbin when you 
travel around China.  
 
My warmest thanks go to Wardit and Zhang Deli, thank you for being my paranimfen. I know 
you did a lot for me, especially when I was in China. Thank you for everything.  
 
Living far away from home is not always easy. I was lucky to have so many Chinese friends 
here in Groningen accompany me through the happy and unhappy days. Dear Niu Xiaoyu, I 
enjoyed all the talks we had, and appreciated your wise words very much. You are not only a 
co-jogger but a friend indeed. Dear Qin Si, I wish everything goes well for you in the United 
States. Dear Zhang Chunling, how about your work in Shanhai? Good luck with your new life. 
Dear Liu Gaifen, thank you for your suggestions concerning my study and my life. I am 
looking forward to meeting you in Beijing in the future. Dear Qin Li, you are a good sport 
mate, and you are more than that. I wish you all the best. Dear Lu Wenli, I know you will have 
your defense on January, and you will travel around Europe with your husband after that. I 
wish you success and enjoy your trip. Dear Lia, Jin Xin, Lang Shuting, Sun Xiaoxiao and 
Camie, I enjoyed our corridor- and kitchen-talk very much. We are from different areas and 






Of course, many thanks to the HMUers: Yu Lili & Qian Cheng, Han Lina & Zhao Yan, Tan 
Hongtao, Wei Yunwei, Yu Hongjuan and Yin Meimei. Dear Cheng and Lili, I really 
appreciated your help at the beginning of my time in Groningen. Dear Hongtao and Yunwei, I 
hope you have your promotion soon. Dear Lina and Yan, your daughter looks so lovely, best 
wishes to her. Dear Hongjuan, I am amazed by your hard work, good luck to you. 
Dear Li Jiang, the 80 km-one-day cycling was really tough, and unforgettable! Thanks to Liu 
Bo, Liu Qi, Liang Zheng, Bu Shaochong, Cai Yingdan, Jiang Yi, Liu Yuxuan, Chen Bing and 
Li Kun. I cherish all the good times we have had in Groningen. Keep in touch and hope to 
see you in Harbin one day.  
 I would like to thank Fu Jingyuan, Ding Ning, Yu Zilin, Zhang Faya & Li Peiqin, Wu Bian & 
Zhou Qiyun, Lee Ee Soo, Ye Qingsong, He Yan, Xue Ruiqi, Liu Xiaomei, Lu Mingtao, Du 
Xiaoguang, Mu Dongdong and Wang Yi. Dear Ning and Zilin, thank you for all your effort to 
unite the students in Groningen. Dear Ee Soo, I will remember that if I want to chat with old 
couples during a cruise, always start with the question, “How many times have you been on a 
cruise?” And, “which is the most unforgettable one?” Dear Jingyuan, you are always kind to 
me, thank you. 
 
I also want to express my gratitude to my supervisor in China. Dear Prof. dr. Yu Bo, without 
your support I would have never achieved my degree in China. I am appreciative of your 
kindness and constant readiness to help me. Thank you. 
 
My special thanks to Zhai Aixia, Diao Liwei, Lu Libo, Liu Haixia, Wang Xiaodong, Li lili and 
Du Wenjuan. Thank you very much for your help.  
 
Finally, never enough thanks to my beloved parents and my sister. Dear Mom and Dad, 
thank you for all the unconditional love you have given to me. I know I am not a perfect 
daughter, but in my eyes, you are always the best parents. My dear sister, thank you so 
much for your support! Dear Tianyu, I feel happy and at peace whenever I hear your sweet 















































Chapter 1-Figure 1, page 11 
 
 












































Chapter 3-Figure 5, page 51 
 
 

























Chapter 6-Figure 3, page 116 
 
C 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B D 
 
